Current News

♢♢ Note: I and others entered into a securities transaction with Provectus in March 2017.

Links to news items from July 2013 to [earlier in] October 2016 may be found on the Archived News page.

Me (February 23, 2017)

Updated below: 3/23/17 and 3/27/17 {thrice}.
Image source
Provectus issued a press release and made an 8-K filing regarding the appointments of Bruce Horowitz and I as special advisers to the board of directors (to advise the board on financial and corporate strategy).

The press release also noted Eric's bridge loan and investment commitment to the Company. See Bridge Building (February 21, 2017).

Updated (3/23/17).1: Provectus issued a press release and made an 8-K filing regarding my and others involvement in a securities transaction with the Company, and my and others involvement with the Company.

Updated (3/27/17).2: Seeking Alpha ("SA") itself/themselves published blog post "Provectus Biopharmaceuticals Announces Terms Of Definitive Financing Commitment" under my name today. The SA version is here. See Returning to Seeking Alpha, sort of (January 21, 2015) on the blog's Archived News III page. My SA account has been dormant since October 2013; I have not published articles or made Instablog posts there myself, nor have I replied to comments under articles SA publishes since.

Updated (3/27/17).3: Emails this morning to SA are below.
Click to enlarge
Click to enlarge
Updated (3/27/17).4: SA follow-up is below:
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge

Image source

Bridge Building (February 21, 2017)

Provectus made an 8-K filing regarding a bridge loan extended to the company by Chief Technology Officer and a co-founder Dr. Eric Wachter, PhD. Notable terms include (but are not limited to):
  • Up to $2,500,000 in principal,
  • A 6% annual interest rate,
  • The loan is unsecured,
  • A maturation date of May 22nd (i.e., 90-day term), and
  • Principal and accrued interest payable at maturation, or convertible into a "qualified equity financing" (defined in the document).
Provectus also made a prospectus supplement filing to update the rights offering document and process regarding Eric's bridge loan.

Clinical Trial Status Updates: Melanoma P3, Melanoma P1 combo w/ pembro (February 20, 2017)

H/t InvestorVillage poster Warlord:

A. PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma, Oklahoma Cancer Specialists and Research Institute was added as a trial site (not yet recruiting). The principal investigator is Dr. Edward Yob, changes for this iteration are here.
Click to enlarge. Image source (without dotted line/box).
B. PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma, Moffitt Cancer Center (Florida) was added as a trial site (not yet recruiting). The principal investigator is Dr. Jonathan Zager, changes for this iteration are here.
Click to enlarge. Image source (without dotted line/box)
C. Although there were other changes, there do not appear to be material modifications, additions and/or changes to the trial protocols.

The P Word (February 16, 2017)

Takeaway #1: '165 combination therapy daughter patent application (continuation of the combination therapy patent, jointly assigned to Provectus and Pfizer), which received a final rejection from the US PTO, has been advanced in the US PTO intellectual property protection process by Provectus. This step was undertaken on January 13th, and I had missed it.
Click to enlarge. Image source: Application on USPTO PAIR website.
With this step advancement, all three combination therapy daughter/continuation application now have been advanced in some form or fashion.

This blog news entry is the expected follow-up to Patently Obvious (January 6, 2017) and You down with I.P.P.? (December 14, 2016). I previously noted under Hey batta batta batta swing batta batta (October 19, 2016) on the blog's Archived News VI page that in tracking (diligencing) Provectus' intellectual property portfolio, all three daughter patent applications -- that is, all continuations of August 2015-awarded patent Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer (#9,107,887) -- received final rejection notices from the US PTO; '309 (application #14/748,579) on September 23rd, '318 (#14/748,634) on October 12th, and '165 (#14/748,608).

Takeaway #2: '318 combination therapy daughter patent application (a continuation of the combination therapy patent, also jointly assigned to Provectus and Pfizer) has been further advanced: A request for continued examination was made on February 10th.
Click to enlarge. Image source: Application on USPTO PAIR website.
Institutional (February 14, 2017)

13F filings (through this writing) for the period ending December 31, 2016, per, showed:
  • A decrease in institutional share holdings of Provectus: ~209K shares (down from 10.6 million as at September 30th, or -98% quarter-over-quarter) and 0.06% of shares outstanding* (not a fully diluted figure) (down from 4.35%), and
  • A decrease in the number of filers to 8 (down from 42).
Click to enlarge
Click to enlarge
* Shares outstanding increased from 244 million (9/30) to 365 million (January 2017) (+49.6%).

Median shares held by reporters/filers decreased to 7,500 (from 26,504).
Click to enlarge
Scripted (February 9, 2017)

Updated below: 2/11/17, 2/13/17 and 2/14/17.

Provectus made two new SEC filings related to the company's conference call today. First, Provectus issued an 8-K that included the call's presentation and script. Second, the company amended the prospectus of the rights offering (i.e., Prospectus Supplement No. 1) to address/include the contents of the aforementioned 8-K.

Maxim Group's Karl Brenza noted: "The Rights Offering is currently scheduled to terminate on February 17th at 5:00 p.m. Eastern time, although management has determined, subject to board approval, to extend the expiration date of the Rights Offering to March 3, 2017. This extension of the expiration date will be announced in a press release as soon as it is approved."

Updated (2/11/17).1: Provectus issued a press release related to its extension of the rights offering to March 3rd.

Updated (2/13/17).2: The company made an 8-K filing related to the abovementioned rights offering extension, and extension press release.

Updated (2/14/17).3: The company made an 8-K filing related to procedures for foreign stockholders and certain warrant holders related to the rights offering.

"Percutaneous Rose Bengal as an Oncolytic Immunotherapy for Hepatic Metastases" (February 7, 2017)

"Percutaneous Rose Bengal as an Oncolytic Immunotherapy for Hepatic Metastases," CIO (Clinical Interventional Oncology) 2017, Hollywood, FL USA, Abstract #15831, February 2017
Click to enlarge
Click to enlarge
Click to enlarge
January Blog Readership Stats (February 1, 2017)
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
The Fifth Wave (January 19, 2017)

Updated below: 1/27/17, 1/30/17, 1/31/17 and 2/3/17.

Provectus issued its fifth amendment to its S-1 related to the rights offering to existing investors today. The fourth amendment is here (filed with the SEC on December 21st). As an aside, the third amendment is here (filed with the SEC on December 6th). 

Updated (1/27/17).1: Provectus issued its sixth amendment to its S-1.

Updated (1/30/17).2: The company's S-1 was made effective on January 27th.

Updated (1/31/17).3: Provectus made two new SEC filings. One was the [presumably] final prospectus for the rights offering, offering up to approximately 20 million units (4 shares of common stock and 0.5 shares of Series C convertible preferred stock per unit) for $1 per unit. One was an 8-K related to the associated press release. A conference call by company management and a Maxim Group (the deal's organizer) representative to discuss the offering is scheduled for February 9th at 4:15 pm ET.

Updated (2/3/17).4: Provectus made a new SEC filing, an 8-K, which discussed certain matters related to the rights offering.

"Intralesional treatment of metastatic melanoma: a review of therapeutic options" (January 14, 2017)

Updated below: 1/16/17.

H/t regular hatter ‏@bradpalm1:
Click to enlarge. Tweet image source
Click to enlarge. Image source
The article references PV-10.
Click to enlarge. Image source above
The abstract is below:
"Intralesional therapy of melanoma patients with locally advanced metastatic disease is attracting increasing interest, not least due to its ability to lead to both direct tumor cell killing and the stimulation of both a local and a systemic immune response. An obvious pre-requisite for this type of approach is the presence of accessible metastases that are amenable to direct injection with the therapeutic agent of interest. Patients who present with these characteristics belong to stages IIIB/C or IV of the disease. Surgical resection with intention to cure is the standard of care for patients with limited tumor burden and confined spread of disease (resectable patients). However, this category of patients is at a high risk of further recurrences until the disease becomes inoperable (unresectable) or progresses to a more advanced stage with visceral organ involvement, after which the prognosis is particularly grim. Most of the intralesional treatments tested so far, including the recently approved oncolytic virus talimogene laherparepvec, target the subpopulation of patients with unresectable disease, but the possibility to use the intralesional treatment in a neoadjuvant setting for fully resectable patients is attracting considerable interest. The present article reviews approved products and advanced stage pharmaceutical agents in development for the intralesional treatment of melanoma patients."
The article notes: "This paper is a Focussed Research Review based on a presentation given at the Fourteenth Annual Meeting of the Association for Cancer Immunotherapy (CIMT), held in Mainz, Germany, 10th–12th May, 2016. It is part of a series of Focussed Research Reviews and meeting report in Cancer Immunology, Immunotherapy."
Click to enlarge. Image source
See also "CIMT 2016: Mechanisms of efficacy in cancer immunotherapy — Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10–12 2016, Mainz, Germany," Kranz et al., Hum Vaccin Immunother. 2016; 12(11): 2805–2812.

Updated below (1/16/17): H/t a regular hatter for the paper itself:
Melanoma is the deadliest of all skin cancers [1] and its incidence has been steadily increasing over the last 30 years [2]...
The propensity of melanoma to metastasize to readily accessible cutaneous or subcutaneous locations has prompted increased interest in researching the development of therapeutic approaches based around direct injection of active agents into the metastases, which have collectively been given the name of intralesional approaches. 
Patients with limited and often asymptomatic locoregional disease are the ones most likely to benefit from intralesional therapies [8, 9]. In fact, direct injection of a therapeutic agent into the tumor, while maximizing its concentration at the site of disease, is associated with reduced systemic concentrations of the drug and a more favorable tolerability profile, when compared to systemic or regional perfusion-based therapies, which normally lead to considerable toxicity. Furthermore, the local effect exerted directly on treated tumor lesions can in some instances be associated with a systemic bystander effect (termed “abscopal effect”). This effect results in the shrinkage or disappearance of non-treated lesions, some of which may even be located at distant anatomical sites... 
...Recently, new promising agents for the locoregional treatment of melanoma lesions have been developed. This review will focus on those agents which have either already obtained marketing approval or are currently being investigated in registration phase 3 trials. These include talimogene laherparepvec (T-Vec, Imlygic™), rose bengal (PV-10), and Daromun (L19IL2 + L19TNF). Many other agents are being developed for intratumoral application in several indications including melanoma but they have not been investigated in controlled phase 3 studies yet; these agents and their application have also been described in excellent recent review articles [17–19].
T-Vec was approved in 2015 in the US and Europe for the treatment of unresectable stage IIIB, IIIC or IVM1a metastatic melanoma. Rose Bengal is currently being investigated in a phase 3 trial in a similar indication. Daromun is being studied in a phase 3 trial as a neodjuvant treatment prior to surgery in fully resectable stage IIIB and IIIC patients (see also Table 1).
Click to enlarge 
...Novel agents: intralesional treatment of unresectable advanced metastatic melanoma patients...
Rose Bengal (PV-10)
Rose Bengal is a small molecule that belongs to the xanthene family and is a derivative of fluorescein. The compound has been in use for decades in the clinic as eye drops to stain damaged conjunctival and corneal cells and thereby more easily identify affected areas. Its potential applicability as an anti-tumor agent has, however, been recognized only much later, during a screening campaign for new photodynamic therapy agents with antineoplastic activity....
...The proposed mechanism of action is based on a selective uptake of the compound through the cell membrane of cancer cells because of its higher fluidity as compared to that of normal cells. PV-10 accumulates in the lysosomes [45], triggering lysosomal release and autolysis of the tumor cells, which is normally complete within 30–60  min. Acute exposure of antigenic tumor fragments to APCs is believed to produce the “bystander” effect observed in non-injected tumors...
Over recent years, there has been a radical change in the management of advanced melanoma patients with the approval of many novel therapeutic agents....
If the killing of the tumor can stimulate a tumor-specific immune response that persists after the tumor is removed, a positive impact may be expected on non-injected lesions. As the treatment with Daromun is short (4 weeks), the procedure can be performed without an unreasonable delay of surgical intervention.
Many researchers believe that the future of intralesional therapies is linked to their use in combination with the new systemic therapies, in particular immunotherapies [40, 41]. Results of the ongoing trials will tell if, in addition, the use of intralesional therapies as neoadjuvants can play a role in the therapeutic approach for resectable melanoma patients in the years to come."
Clinical Trial Status Update: Melanoma P3 (January 9, 2017)

H/t a regular hatter: PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma, Wake Forest Baptist Health has started recruiting, and the anticipated primary completion date (Estimated Primary Completion Date) was pushed back from March 2018 to September 2018 (i.e., +6 months). changes for this iteration are here.

Patently Obvious (January 6, 2017)

Takeaway: '309 combination therapy daughter patent application (continuation of the combination therapy patent, PV-10 + targeted therapies), which received a final rejection from the US PTO, has been advanced in the US PTO intellectual property protection process by Provectus.

This blog news entry is the expected follow-up to You down with I.P.P.? (December 14, 2016). I previously noted under Hey batta batta batta swing batta batta (October 19, 2016) on the blog's Archived News VI page that in tracking (diligencing) Provectus' intellectual property portfolio, all three daughter patent applications -- that is, all continuations of August 2015-awarded patent Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer (#9,107,887) -- received final rejection notices from the US PTO; '309 (application #14/748,579) on September 23rd, '318 (#14/748,634) on October 12th, and '165 (#14/748,608).

Provectus' CTO Dr. Eric Wachter, PhD, in his re-submission to the US PTO of the '309 patent application sought no ammendments to the original application, apparently arguing the result of the combination of PV-10 and systemic targeted cancer therapy is/was unexpected, thus novel, and thus patentable.

The re-submission's "Applicant Arguments/Remarks Made in an Amendment" is worth a read, and screenshots are below.
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
Application '165 (continuation of the combination therapy patent, jointly assigned to Provectus and Pfizer) remains to be re-submitted.

Response (January 2, 2017)

Updated below: 1/10/17 and 1/27/17.

Provectus' former interim CEO, and COO Peter Culpepper today filed a Schedule 13D in which he responded to his termination. See And then there were two (December 28, 2016) below.

Updated (1/10/17).1: New SEC filing. Peter filed a Form 4 yesterday, with a remark on the form of "On December 28, 2016, the reporting person, Peter Culpepper, was terminated as an officer and an interim officer of Provectus Biopharmaceuticals, Inc. (the "Issuer"). This Form 4 serves as his exit filing. No acquisitions, dispositions or other transactions involving securities of the Issuer are being reported on this Form."

Updated (1/27/17).2: New SEC filings. Peter filed an amended Schedule 13D today, attached to which he presented his slate of directors for election at the 2017 annual meeting of stockholders. An associated Schedule 14A also was filed.

December Blog Readership Stats (January 1, 2017)

Updated below: 1/3/17 {twice}.
Click to enlarge 
Click to enlarge
Click to enlarge
Click to enlarge
As noted on the blog's Disclosures page, my last tweet was of a November 30th news item. The @PVCTinvestor Twitter account remains open but no longer tweets blog posts or news items (or anything else).

Updated (1/3/17).1: Provectus issued a press release today, writing there would be a business update conference call with investors/shareholders (to address management changes) on Thursday, January 5th. I understand there will be no call, and that the issuance of the release was an error (on the part of the company's investor relations firm Porter Levay & Rose).

Updated (1/3/17).2: Provectus confirmed the cancellation of the abovementioned business update call. See this link here, and screenshot below.
Click to enlarge
And then there were two (December 28, 2016)

Provectus terminated (fired) the company's interim CEO, and COO today, based on "...based on the results of the investigation conducted by a Special Committee of the Company’s Board of Directors regarding improper expense advances and reimbursements to..." Peter, issuing an associated press release and filing an associated 8-K. Of note [to me]:
"In the interim, Timothy C. Scott, Ph.D, will perform the functions of the chief executive officer position in his capacity as President while the chief executive officer position remains vacant."
Quite quiet (December 20, 2016)

Updated below: 12/21/16 {thrice}.

1. John Carroll, Endpoints News, December 20th, "Bristol-Myers doubles down on PsiOxus in $936M-plus “armed” oncolytic virus deal:"
"Amgen has helped pioneer the field with its approval of Imlygic (T-Vec), but PsiOxus and a growing lineup of upstarts on both sides of the Atlantic are following systemic infusions for next-gen programs that promise to do significantly better."
The "field" above is oncolytic virus (OV) (as opposed to oncolytic immunotherapy, or intralesional therapy). PsiOxus appears to be exploring predominantly or exclusively systemic delivery.

2. NG-348's mechanism of action (the OV compound Bristol-Myers licensed above):
Click to enlarge. Tweet image source
3. "Rapid Removal of Hazardous Rose Bengal Dye Using Fe(III) Montmorillonite as an Effective Adsorbent in Aqueous Solution," Vinuth et al., March 2016, Journal of Environmental & Analytical Toxicology. The article references "Toxic effect of rose bengal dye on the living human corneal epithelium," Tabery, Acta Ophthalmol Scand. 1998 Apr;76(2):142-5:
"PURPOSE: To investigate whether rose bengal dye at a concentration of 1% has a toxic in vivo effect on the human corneal epithelium... 
CONCLUSIONS: The appearance of green microdots after the application of rose bengal was probably due to the interruption of intercellular junctions and the penetration of fluorescein stained fluid below the superficial cells. Whether this phenomenon reveals an unhealthy corneal surface and thus has a clinical significance has to be further investigated."
See "Rose Bengal 1% Ophthalmic Solution."

PV-10, Provectus' lead oncology compound, is a 10% solution of Rose Bengal. PH-10, the company's lead dermatology compound, is a 0.001% to 0.01% gel of the active pharmaceutical ingredient.

"Dyes which are discharged from textile industries are major cause for environmental contamination. Most of the dyes are made to be chemically stable and highly persistent in environment. The wastewater released from textile industries contains highly colored pigments causes serious impact not only on aquatic life but also human beings by producing carcinogenic effects [1]. Among different types of dyes, xanthene dyes are most widely used and these are characterized by presence of xanthenes nucleus with aromatic groups as chromophore [2]. Rose bengal is an important xanthene dye widely used in textile and photochemical industries whose molecular structure as shown in Figure 1a. It has severe toxic effects on the human health especially on corneal epithelium [3]. This dye is very dangerous when it comes to contact with skin and causes itchiness, irritation, reddening and blistering. It also affects to eyes like inflammation, eye redness, itching etc. [4]."
[1] Dutta AK, Maji SK, Adhikary B (2014) γ-Fe2O3 nanoparticles: An easily recoverable effective photo-catalyst for the degradation of rose bengal and methylene blue dyes in the waste-water treatment plant. Mater Res Bull 49: 28-34.

[4] Vinoda BM, Manjanna J (2014) Dissolution of iron in salicylic acid and cation exchange between Fe(II)-salicylate and Na-montmorillonite to form Fe(II)-montmorillonite. Appl Clay Sci 97: 78-83.

I can't seem to conform Vimuth's statement regarding "severe toxic effects on the human health" with the author's supporting information. Nevertheless, I think it is relevant to reproduce the material in this blog news entry.

4. Msg 5598. Denmark. Etc. (who, what, when).

5. I'm led to believe Provectus will have two abstracts at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Shanghai in February 2017. For PV-10's two step approach to treating cancer, I wonder if one abstract deals with ablation (step #1) (local) and one deals with immunotherapy (step #2) (systemic); or, if one further discusses the original liver Phase 1 patients, and the second addresses the expanded liver Phase 1 trial patients.

Updated (12/21/16).1: 6. H/t InvestorVillage poster canis_star, "Talimogene laherparepvec in melanoma: Added benefit not proven," German Institute for Quality and Efficiency in Health Care (IQWiG).

Following the approval of intralesional (IL) agent/oncolytic virus (OV)/oncolytic immunotherapy T-Vec (or Imlygic®) in October 2015, which required Provectus' pivotal melanoma Phase 3 trial protocol to be amended (i.e., version 1.2, February 16, 2016), spotty commercial availability of T-Vec has complicated the execution of Provectus' registration study.
Click to enlarge. November 14th 3Q16 business update conference call
Provectus' pivotal trial compares PV-10 (Rose Bengal) with systemic chemotherapy (dacarbazine, temozolomide) or OV therapy (T-Vec) for locally advanced cutaneous melanoma (Stage IIIB-IV M1a, in-transit mets, etc.). The choice of comparator (dacarbazine, temozolomide or talimogene laherparepvec) is up to the investigator at a clinical trial site (i.e., "investigator's choice").

In Australia, for example, it would appear, where T-Vec is approved but not commercially available (it is available for clinical trials using T-Vec run by Amgen), a patient with in-transit melanoma (in transit mets) is considered a candidate for T-Vec as the de facto standard of care (SOC) for this patient population (which also is the same population for Provectus' pivotal trial). Chemotherapy would not be offered to these patients because of the de facto SOC; however, because T-Vec is not commercially available, these patients are steered towards other clinical trials or offered other immunotherapy drugs.

Going forward, there appear to be two geographic-oriented-as-it-relates-to-T-Vec-availability patient recruitment and enrollment tracks. First, where T-Vec is commercially available, like Germany, Provectus Phase 3 trial sites will be set-up, where enrollment is expected to be high. Here, in Germany, T-Vec is both de facto and bona fide SOC -- that is, appropriate for the patient population (i.e., de factoand commercially available to be offered to these patients (i.e., bona fide).
Click to enlarge. November 14th business update call
Second, where T-Vec is not approved (and not available at all) (neither bona fide nor de facto SOC), Provectus Phase 3 trial sites will be set-up, like Russia, Argentina, Mexico, Brazil and China.

Of course, questions (among many others) that beg answers from Provectus Dr. Eric Wachter, PhD, would include: when did you know that spotty availability of T-Vec -- and thus the tussle between de facto and bona fide SOC -- would complicate the company's Phase 3 trial?; when did you implement the course correction(s)?; etc.

Although there appears to be no patient stratification requirement for the trial's comparator arm (i.e., not minimum number of patients treated with T-Vec of the investigator's choices), site selection (as it relates to the first track above) appears to be focused on locations (sites, countries) where T-Vec is commercially available.

Updated (12/21/16).2: 7. Provectus issued its fourth amendment to its S-1 related to the rights offering to existing investors today. The third amendment is here (filed with the SEC on December 6th). Changes between the two documents (using Diffchecker) include (but are not limited to) the below (third amendment on the left, in red/pink; fourth amendment on the right, in green/light green).
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
Updated (12/21/16).3: 7b.
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
Click to enlarge
Class action (December 15, 2016)

H/t a regular hatter: The class action settlement appears to have been finalized on December 12th.
Click to enlarge. Screenshot from the document.

Image source
You down with I.P.P.? (December 14, 2016)

Takeaway: '318 combination therapy daughter patent application (continuation of the combination therapy patent, jointly assigned to Provectus and Pfizer), which received a final rejection from the US PTO, has been advanced in the US PTO intellectual property protection process by Provectus.

I previously noted under Hey batta batta batta swing batta batta (October 19, 2016) on the blog's Archived News VI page that in tracking (diligencing) Provectus' intellectual property portfolio, all three daughter patent applications -- that is, all continuations of August 2015-awarded patent Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer (#9,107,887) -- received final rejection notices from the US PTO; '309 (application #14/748,579) on September 23rd, '318 (#14/748,634) on October 12th, and '165 (#14/748,608).

I also wrote at the time that I did not read too much into these final rejections, noting that the process of prosecuting a patent application is a bit like going to bat in baseball, where there are, in general, three strikes before you are out (i.e., receive a final rejection). The are exceptions, however, such as when an examiner makes an office action "final" earlier if he or she feel the application is not advancing prosecution of the case, or when the applicant resets the strike counter by filing a "request for continued examination" (RCE) (which requires remittance of an additional fee to the US PTO).
"Request for continued examination: A request for continued examination (RCE) is a request by an applicant for continued prosecution after the patent office has issued a "final" rejection or after prosecution "on the merits" has been closed (for example by a Notice of Allowance (NOA)). An RCE is not considered a continuing patent application - rather, prosecution of the pending application is reopened. The inventor pays an additional filing fee and continues to argue his case with the patent examiner." (source: "Continuing patent application" Wikipedia page
Further, I wrote, extending the baseball analogy, an out at a given at-bat does not mean there cannot be additional at-bats, but something has to happen after the out to get another at bat. In Provectus' three cases, I imagined (believed) it would be paying the fees so as to continue claiming what ground the company can in the combination therapy space. The intellectual property game is played first by swinging for the upper deck (i.e., claiming "everything"), which probably leads to a strike, and then second by focusing a bit more, and so on, until an appropriate balance is achieved between the breadth of claims and allowable ones. In particularly difficult examinations, it may even be necessary to abandon the case and follow it up with a continuation, in this case perhaps adding some additional details to the specification that support the desired claims.

I also discussed other aspects of Provectus I.P.P. (portfolio or protection) under Is Pfizer paying more [IP] attention to Provectus? (September 2, 2016), noting that in late-August Provectus and Pfizer advanced '318 (PV-10 + immunomodulatory cancer agents) by providing a response to the US PTO's non-final rejection action through revised claims and that included Provectus- and Pfizer-filed terminal disclaimers.

'318's current status as of December 13th is below:
Click to enlarge. Screenshot from PAIR.
Provectus' CTO Dr. Eric Wachter, PhD et al. amended claim #59 and added new claim #75 (and cancelled claim nos 60-61 and 73).

1. Claim #59 amendment:
Click to enlarge. PAIR screenshot
2. Claim #75 addition:
Click to enlarge. PAIR screenshot
Click to enlarge. PAIR screenshot
When has Rose Bengal's clinical value proposition let you down? (December 8, 2016)

Today's announcement by Provectus and the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) to develop the framework for and then potentially explore the use of PV-10 in pediatric cancer*, Rose Bengal's global pharmacoeconomic value proposition continues to grow both broadly and deeply.

Rhetorical question: If (a) PV-10 is considered an ablative immunotherapy, (b) has shown efficacy (how much may depend on the beholder or observer), and (c) has been used in children as a liver function diagnostic (131I-Rose Bengal) starting in the 1960s, what are the, um, you know, chances it might, um, you know, work safely in pediatric patients?

1963: White et al., PEDIATRIC APPLICATION OF THE RADIOIODINE (I-131) ROSE BENGAL METHOD IN HEPATIC AND BILIARY SYSTEM DISEASE, Pediatrics. 1963 Aug;32:239-50. (Departments of Radiology, Pediatrics, and Surgery of The Children's Mercy Hospital, Kansas City, Missouri)

1972: Effect of Phenobarbital on Hepatic Transport and Excretion of 131I-Rose Bengal in Children with Cholestasis, Thaler et al., Pediatric Research 6(2):100-10 · February 1972.

1973: Diagnosis of extrahepatic biliary obstruction in infants by immunochemical detection of LP-X and modified 131I-Rose Bengal excretion test, Poley et al. Translational Research, March 1973 Volume 81, Issue 3, Pages 325–341.


* See also December 8, 2016 blog post Rose Bengal (PV-10) + Oncology + Pediatrics.

Fundraising (December 6, 2016)

Updated below: 12/6/16 {thrice}, 12/7/16 {twice} and 12/9/16.

In a filing made today, Provectus amended its prior amended S-1 (November 22nd) to an S-1 that proposes to raise $48.75 million (+ 20% maximum offering) in exchange for preferred stock and a royalty payment of the from net sales of PV-10 and PH-10.

Updated (12/6/16).1: There is a lot to digest in this new financing structure (i.e., the December 6th S-1/A; common stock, preferred stock, royalties) compared to the old one (i.e., November 22nd/November 1st/October 5th; common stock, warrants on common stock). One preliminary or quick reaction for now is this: the royalty structure feels/look like a liquidation preference, where the question I have is whether it (the liq pref) is nonparticipating or participating, and after which existing common stockholders then receive proceeds of value from "Royalty Payments, Fundamental Transaction Payments and Liquidation Payments."

Updated (12/6/16).2: From top to bottom...
  • There are no pricing specifics as yet.
  • It could be that one (1) unit of this offering would comprise or consist of (a) one (1) share of common stock, (b) one (1) share of Series C Convertible Preferred Stock (convertible into eight (8) shares of common stock), (c) a two- (2-) year, seven percent (7%) per year payable in kind (PIK), cumulative dividend, and (d) some amount of monies from license royalties/transaction payments involving the drug(s) and the company [or some such construct, with specifics to follow of course].
Updated (12/6/16).3: (a) provides the opportunity for offering participants, particularly Maxim clients whose investment style and strategy aligns with such, to sell the common stock portion of the unit so as to lower their cost basis.
  • 8% cash fee to Maxim Group. This is the third consecutive financing transaction undertaken by Maxim on behalf of Provectus.
  • Nonparticipating liq pref?: "Upon conversion of any shares of Preferred Stock (the “Converted Shares”) to common stock prior to the payment of the Maximum Payment Amount in full, the holder of such Converted Shares shall no longer be entitled to receive any Royalty Payments, Fundamental Transaction Payments or Liquidation Payments for such Converted Shares and the Maximum Payment Amount will be reduced by the maximum amount of any remaining Royalty Payments, Fundamental Transaction Payments and Liquidation Payments, if any, that the holder of the Converted Shares would have been entitled to receive had such holder not converted such shares."
  • The so-called Applicable Percentage ladder table:
Click to enlarge
H/t a shareholder: A discussion with a Memorial Sloan Kettering Cancer Center nurse in a bar (queue the jokes), paraphrasing -- Do you know what Keytruda is? Yes. Do you know what Opdivo is? Yes. Do you know what CAR-T is? Yes. Do you know what PV-10 is? Yes.

Updated (12/6/16).3: A table comparing the changes in the S-1/As
Click to enlarge
Updated (12/7/16).4: More top to bottom...
  • "PV-10 Melanoma: Phase 3 study in progress: Opened recruitment in U.S. in April 2015; expected expansion from limited sites in U.S. to sites in Europe, Latin America and Asia in 2017 in order to increase enrollment"
  • "PV-10 + Pembrolizumab: Phase 1b/2 study initiated September 2015; phase 2 portion expected to commence in 2017"
  • "PV-10 Cancers of the Liver:...Phase 1b/2 commencement expected in early 2017"
  • "PH-10 Psoriasis (Mechanism of Action): Phase 2 study data being compiled for FDA end of Phase 2 meeting"
  • "On the Price Reset Date, the Adjusted Conversion Price was set at $0.0533 pursuant to the terms of the Certificate of Designation. Accordingly, on November 28, 2016, we issued holders who had previously converted their shares of Series B Preferred Stock 112,442,685 shares of common stock pursuant to the price reset provisions in the Certificate of Designation, and we are obligated to issue an additional 6,330,316 shares of common stock, which shares are currently being held in abeyance pursuant to beneficial ownership limitations."
  • "On the Price Reset Date, the Adjusted Exercise Price was set at $0.0533 pursuant to the terms of the August 2016 Warrants. No holder of August 2016 Warrants had exercised its August 2016 Warrants prior to the Price Reset Date, so no additional shares of common stock were due to holders of August 2016 Warrants as of the Price Reset Date. Holders of August 2016 Warrants are entitled to exercise their August 2016 Warrants at the Adjusted Exercise Price and will receive an aggregate of 112,564,964 shares of common stock upon exercise of the August 2016 Warrants."
  • "Our cash and cash equivalents were $5,178,076 at September 30, 2016, compared with $14,178,902 at December 31, 2015. As of November 30, 2016, we had cash and cash equivalents of $2,627,521."
Updated (12/9/16).6: A cursory perspective, and outsider analysis based merely on math (e.g., a lower average monthly cash burn for October and November), would suggest cash could last through the end of January. This of course begs the question, why the "rush" to undertake the rights offering? Think, and then do. Mostly the same message, different messenger(s) and voice(s).
Updated (12/7/16).5: 
  • "Our Phase 3 clinical trial of intralesional PV-10 as a melanoma treatment opened to enrollment in the first half of 2015, and we are actively recruiting and treating patients in centers in the U.S. and Australia. We are seeking 225 patients for this study, and although initial enrollment has been unacceptably slow due to evolving care standards and intense competition for patients and investigator resources in our traditional regions of clinical development in the U.S. and Australia, we have initiated steps to expand the study to include a total of 61 centers in the U.S., Australia, Europe, Russia, Latin America and China by the end of 2017; this is a substantial increase from 30 sites in the U.S., Australia and Europe that we projected would be necessary at the start of the study, and reflects the need to compete for patients on a global scale for large, specialized oncology studies. The primary outcome measure is progression-free survival, PFS, to be assessed every 12 weeks up to 18 months. The secondary outcome measures include complete response rate, CRR, and its duration to be set every 12 weeks up to 18 months and overall survival to be assessed every 12 weeks up to 18 months. Unlike our Phase 2 study, which was a single arm study, the Phase 3 study is a randomized trial. And we hope to demonstrate conclusively that PV-10 is both safe and effective and is statistically superior to the control therapy, investigator’s choice of systemic chemotherapy or intralesional oncolytic viral therapy. Our estimated primary completion date is September 2018, and an estimated study completion date of October 2018. This compares to an estimated primary completion date of September 2017, and an estimated study completion date of October 2017, we made at the time of study initiation, and reflects cumulative delays in site startup and patient accrual due to competition for patients and investigator resources and rapidly evolving care standards for melanoma patients in the U.S. and Australia. When 50 percent of the events required for the primary endpoint have occurred, the Independent Data Monitoring Committee will report an interim assessment of efficacy and safety. So, meaningful clinical data could come well before the primary completion date, as documented on"
    Click to enlarge. Prior S-1/A LEFT, Current S-1/A RIGHT
    • "Our lead CRO is coordinating global safety monitoring (pharmacovigilance) appropriate for our growing global clinical operations, and establishment of an independent Clinical Trial Data Monitoring Committee (DMC) to provide independent oversight of our phase 3 melanoma study. The FDA states “A clinical trial DMC is a group of individuals with pertinent expertise that reviews on a regular basis accumulating data from one or more ongoing clinical trials. The DMC advises the sponsor regarding the continuing safety of trial subjects and those yet to be recruited to the trial, as well as the continuing validity and scientific merit of the trial.” The DMC will ensure that our study provides patients with maximum possible safety while protecting the scientific validity and integrity of the data we gather."
    Click to enlarge.
    • "In November 2016 at the Society of Immunotherapy of Cancer Annual Meeting in Washington, our collaborators at Moffitt Cancer Center reported preliminary data on combination of intralesional PV-10 with systemic gemcitabine, using murine models of metastatic pancreatic adenocarcinoma. Gemcitabine is a standard chemotherapeutic agent used to treat pancreatic cancer, and the Moffitt team showed that PV-10 ablation of pancreatic cancer tumors led to immunologic activation comparable to that previous reported for melanoma, breast carcinoma and colorectal tumors. Addition of gemcitabine enhanced these effects of PV-10, possibly via suppression of myeloid derived suppressor cells (MDSC), which decrease in response to gemcitabine. Since MDSC have an inhibitory effect on a number of immune effector cells, including CD8+ T cells, dendritic cells and NK T cells, the apparent combination effect could result from reduced immune suppression by gemcitabine coupled with immunologic stimulation by PV-10. According to statistics from the America Cancer Society, over 53,000 new cases of pancreatic cancer are expected in the U.S. in 2016, with 41,780 deaths and a 5-year survival of 8%. What we have learned so far about percutaneous PV-10 injection into liver cancers could have applicability to an exploratory clinical study of this cancer where any progress is likely to be clinically meaningful."
    Image source
    A whale of a story (December 6, 2016)

    InvestorVillage (IV) poster pvct-whale noted the exercise price of warrants issued as part of Provectus' Maxim-led August preferred stock and warrant fundraising, post-price protection calculation or determination, as $0.0533:
    "...the Conversion Price of the Preferred Stock has been adjusted from $0.25 per share to $0.0533 per share (the "Adjusted Conversion Price"), and the Exercise Price of the Warrants has been adjusted from $0.275 to $0.0533 (the "Adjusted Exercise Price")."
    See also Aftermath (November 30, 2016) below.

    Bridge building (December 5, 2016)

    Intralesional (IL)/oncolytic therapy, melanoma and Rose Bengal/PV-10 key opinion leader (KOL) Dr. Sanjiv Agarwala, MD presented "Innovative combination strategies - oncolytic therapy and systemic immunotherapy approaches" at Melanoma Bridge 2016 in Naples, Italy on December 2nd. He presented "Overview of intralesional oncolytic therapy" at Melanoma Bridge 2015.

    Differences and similarities, and notables from the presentations include but are not limited to:
    Click to enlarge. LEFT 2015; RIGHT 2016
    Click to enlarge. LEFT 2015; RIGHT 2016
    Click to enlarge. LEFT 2015; RIGHT 2016
    Click to enlarge. 2016
    Click to enlarge. 2016
    Click to enlarge. 2016
    Click to enlarge. LEFT 2015; RIGHT 2016
    Click to enlarge. LEFT 2015; RIGHT 2016

    Image source
    Aftermath (November 30, 2016)

    Updated below: 11/30/16 and 12/1/16.

    1. Maxim's Dan Ballestra and InvestorVillage (IV) poster pvct-whale (aka pvct in cleveland, PVCT Fixer) were originally correct regarding the tradability (lack of restriction) of the so-called ratchet stock and warrants. Someone else was not, despite his excuses or revisionism or parsing to the contrary.

    2. IV pvct-whale offered up a calculation of the additional securities potentially issued under the August preferred stock fundraising's price protection as approximately 226 million -- his figure of stock and warrants per million dollars of investment times my use of the $6 million gross proceeds figure. This number would include the original preferred stock as converted into common stock plus warrants (a total of 48 million), which would adjust into the number above (but does not include dividends as shares). IV agrossfarm had estimated approximately 270 million (I cannot easily find the associated IV link), while IV rmgillis had estimated 295 million. As always, I am grateful to other shareholders for posting information that is potentially (likely) accurate (or sufficiently "in the ballpark") and useful.

    Provectus has not yet made a filing that reveals the above number; however, with about 305 million shares, options and warrants out prior to the August financing, the potential fully diluted figure as of this writing might be approximately 530 million, leaving about 450-470 million for future needs.

    3. What's next boys? [a rhetorical question]

    Updated (11/30/16).1: 4. Provectus issued a press release and filed an associated 8-K regarding its stock exchange listing status, Announces Notification of NYSE MKT Listing Deficiency. Of note [to me]:
    "The Company is required to submit a plan to the NYSE MKT by December 23, 2016 advising of actions it has taken or will take to regain compliance with the continued listing standards by May 23, 2018. The Company's management is exploring its options moving forward. Currently, the Company intends to submit a plan by the December 23, 2016 deadline."
    Updated (12/1/16).2: 5. November blog readership stats.
    Click to enlarge
    The yays have it. The nays have it, too. (November 28, 2016)

    Provectus' special shareholder meeting was held earlier today. The results were available in the morning if you were apprised of them by a shareholder in attendance, and comprised an 8-K filed by the company today. Proposal number 1 was approved 78%-21% (+56%). Proposal number 2 was rejected 47.9%-49.8% (-1.9%), with 2.2% abstaining. See the table below.
    Click to enlarge
    Proposal number 2 was always a not-so-easy proposal on which to make a quick decision in terms of the rationale for voting for or against it. A reverse split (RS) does provide Provectus with the best opportunity to raise the entire amount the company seeks via the existing investor rights offering (RO) (assuming full or oversubscription). Yet, the average shareholder could not trust neither the board nor management with (a) the discretion to undertake an appropriate RS, (b) the responsibility of choreographing the pricing of the RO and subsequent news (given the backdrop of an RS), and (c) prudently spending the money raised from the RO.

    I'm led to believe so-called ratchet stock and warrants would be issued to August preferred share fundraising investors on or around November 30th. See Phase 3 guidance (November 21, 2016) below.

    Perhaps the rejection of proposal number 2 might hasten a sense of urgency in the independent directors to welcome the assistance of others, and implement a different finance-corporate development-marketing-company culture-etc. plan than the one they're currently carrying out. It's not hard to improve over a blank piece of paper, but I think and believe we can...substantially.

    Image source
    Thanksgiving sides (November 24, 2016)

    Updated below: 11/25/16 and 11/26/16.

    1. Juno Therapeutics said this week two more patients died in one of its clinical trials, following three deaths reported in July. See Fortune's November 23rd article "Juno Therapeutics' Shares Sink After 2 More Deaths in Leukemia Drug Trial."

    Wikipedia's tumor infiltrating lymphocytes (TILs) page describes TILs as "a type of white blood cell found in tumors." It goes on to say that "TILs are implicated in killing tumor cells. The presence of lymphocytes in tumors is often associated with better clinical outcomes." The National Cancer Institute's Dr. Steve Rosenberg, MD, PhD pioneered the approach of using TILs via adoptive cell transfer (ACT) to treat cancer patients. The American Cancer Society notes that TILs are "immune system cells deep inside some tumors...These T cells can be removed from tumor samples taken from patients and multiplied in the lab by treating them with IL-2. When injected back into the patient, these cells can be active cancer fighters." One company taking this approach of ACT via TILs is Lion Biotechnologies (NASDAQ: LBIO).

    Another variation on this concept of ACT is where immune cells originating from a patient's blood (as opposed to his or her tumor) are extracted, altered and put back "with the goal of transferring improved immune functionality and characteristics along with the cells." Peripheral blood T cells are genetically engineered to express tumor-antigen specific T-cell receptors. Companies using this approach include Bluebird Bio (BLUE), Juno Therapeutics (JUNO) and Kite Pharma (KITE). See April 21, 2016 blog post Burning Down The House.

    The biggest advantage of ablative immunotherapy -- that is, Rose Bengal and PV-10 -- is the education of the immune system in the proper context, which was a prediction of Provectus' former Chairman and CEO, and a co-founder Dr. Craig Dees, PhD from the beginning of the drug compound's development. The further one strays from in situ activation of the immune system, the greater the risk of unpredictable outcomes.

    Provectus CTO Dr. Eric Wachter, PhD previously has conversed about raw hamburger and a well done hamburger. Both are quite different materials along many dimensions, but they both are still hamburger.

    Properly destroying cancer tumors means killing only tumors and doing so completely, quickly and, very importantly, safely (that is, leaving healthy tissue unharmed). They believe this approach is the only effective way of sustainably stimulating a person’s natural anti-cancer defenses. Instead of bathing the entire body or even parts of it with radiation, or filling the bloodstream with oral or intravenous chemotherapies or present-day immunotherapies, Dees et al. firmly hold the position that stimulating the immune system is best achieved through treating tumor tissue by injecting into it a drug capable of destroying the entire tumor as quickly as possible without damaging surrounding healthy cells. Completely also means everything from visible tumor tissue to occult or hidden cells in and immediately around the injection site. Quickly means having the drug processed through and excreted from the body in short order. Antigens generated from the tumor destruction caused by drug injection then can be presented to the body’s cells responsible for selecting the best and most relevant antigens in order to encourage cancer-killing cells to replicate themselves throughout the body. Importantly, tumor antigens have to be viewed in context; physical tumor destruction techniques such as heating or freezing tissue destroyed fragile antigens and disrupted their relevant contextual structures. Disruption of cell membranes and removal of lipids, proteins, and complex carbohydrates destroy the antigens’ context, which is to what immune system cells respond. Thermal destruction denatures potential antigens, changing their chemical structure so that they were no longer representative of the tumor cell. In order to work rapid destruction of tumors has to preserve both antigenic structure and biological context.

    History: April 2, 2013 blog post $PVCT: Treating Cancer Like An Infectious Disease by Craig Dees.

    Juno's issues can have major ramifications for any technology. Eric would argue for Provectus' measured approach to development, which is mostly (but not completely) compelling in regards to the clinical side of the business; however, given the state of the financial side of the business, Eric's argument is mostly insufficient and (as I've mentioned before) not the least bit disconnected.

    2. As Eric noted on Provectus' November 14th 3Q16 business update call, spotty availability of Amgen's intralesional (IL) and oncolytic virus (OV) -- oncolytic immunotherapy -- T-Vec has complicated and presumably continues to complicate Provectus' pivotal Phase 3 trial. If PV-10 is approved, I would imagine Eric does not anticipate concern about key headwinds Amgen faced and still faces with T-Vec (e.g., biosafety restrictions for a GMO live virus, a cryogenic supply chain, regulatory clarity, etc.). In the EU, T-Vec was approved based on a subgroup analysis of Stage IIIB-IV M1a patients. It appears that in Australia reimbursement efforts used the U.S. basis for approval (i.e., Stage IIIB-IV M1c patients), which was good for the breadth of IL OV's labeling but complicates its pharmacoeconomics.

    3. Where is Allison+Partners?

    4. During this year "affiliates" of Provectus -- that is, investigators and sites using PV-10 -- produced the following abstracts, posters and presentations (in chronological order), which was pretty considerable in my view (seven pieces of work):
    • Preclinical: PV-10 monotherapy (PV-10 for colon cancer), University of Illinois at Chicago, "PV-10 Induces Potent Immunogenic Apoptosis in Colon Cancer Cells," ASC, February, 
    • Clinical: PV-10 monotherapy (PV-10 for in transit melanoma), (2), Princess Alexandra Hospital and Peter MacCallum Cancer Centre, "Intralesional PV-10 Chemoablation Therapy for the Treatment of Cutaneous Melanoma Metastases - Results of a Prospective, Non-Randomised, Single Centre Study" and "Intralesional PV-10 for In-Transit Melanoma - A Single Centre Experience," respectively, Royal Australasian College of Surgeons 85th Annual Scientific Congress, May,
    Different voice(s). Same considerable message.

    5. Why was there a dearth of new clinical trial data from Provectus in 2016 or, at the very least, clinical trial updates (e.g., enrolment figures, some substantial commentary beyond "interesting," etc.)? I imagine the company was engrossed in building and assuring the company and trial's infrastructure was sufficiently sound to support a global Phase 3 registration study (no small feat), which included (as we learned on the November 14th update call) a major commitment to Europe starting in 2017. Of course, a management shakeup (February) and its long tail did not help.

    6. Given number 5 above, however, 2017 would appear to be setting up quite well for at least four Provectus clinical datasets:
    1. Mechanism of action (PH-10 for psoriasis),
    2. Monotherapy (PV-10 for liver, expanded Phase 1),
    3. Combination therapy (PV-10 + checkpoint inhibition for melanoma, Phase 1b), and
    4. Monotherapy (PV-10 vs. chemotherapy and OV for melanoma, Phase 3 interim data assessment).
    Updated (11/25/16): 7. Apparently in keeping with what I noted a couple of times below -- see Pancreatic adenocarcinoma (November 14, 2016) and "FAQs" (November 22, 2016) -- it would appear the retail broker side (e.g., purportedly Dan Ballestra [apparently yet again]) of Maxim Group continue to say to clients (based on multiple reports today, which may be referring to the same conversation with the same broker, or maybe more than one conversation with more than one broker), perhaps among other things, that (i) the additional securities to be issued related to the August preferred share fundraising price protection are unrestricted (the so-called "ratchet stock" [and warrants] to some), (ii) to sell (dump) all ratchet stock and keep [ratchet] warrants, and (iii) if the proposal to provide the board of directors with discretion to undertake a reverse split is not approved, the company will go under.

    Updated (11/26/16): 8. Trying to keep it simple, my takeaway for number 7 above is that the rep's/reps' message is straightforward and understandable (from his/their perspective). The message is, one would hope, a fiduciary one to the client, which is the investor or participant in the August preferred stock fundraising (it is not Provectus). (a) If you believe or know the ratchet stock is unrestricted, you blow it out to reduce your cost basis, and then use the ratchet warrants to improve your investment return. (b) The company said it required at least $15 million to complete its pivotal melanoma Phase 3, melanoma combination therapy Phase 1b/2 and liver Phase 1b/2 programs, and was hoping or planning to raise $17.5 million and the 20% oversubscription amount (i.e., a total of $21 million); without a reverse split, it would be difficult to impossible to do so -- thus, if it doesn't raise enough money before a milestone, non-dilutive financing event occurs, it runs out runway and hence goes under. The rep/reps are not rocket scientists (and neither am I).

    There is hard work to be done (which mostly refers to non-clinical aspects of the business) to dramatically change the trajectory of the company, but such work can be successfully carried out (but that is not the message the rep/reps are obliged to convey). If only folks would ask for help...

    9. Provectus' COO and interim CEO Peter Culpepper did an interview with Small Cap Nation's (SCN's) Jane King, which aired on November 23rd on YouTube:
    Of note [to me] (paraphrasing below):
    • [1:03] PV-10 can become standard of care for Stage III melanoma if the company's pivotal melanoma Phase 3 trial is successful,
    • [5:56] The company can always uplist back onto the NYSE MKT, or uplist onto the Nasdaq, pending news, corporate partnerships, etc. (aka milestones).
    I thought it was a useful piece, but its lack of effect (thus far) could serve as a reminder to shareholders the message below is powerful, but the messenger's voice has grown stale, perhaps is tired, and clearly is being ignored by many to most.
    Click to enlarge. Image source

    "FAQs" (November 22, 2016)

    Updated below: 11/22/16 {four times} and 11/23/16.

    Provectus posted "frequently asked questions" ("FAQs") related the company's November 14th 3Q16 business update conference call. The answers to the questions in the material provided on Provectus' new website (the Quarterly Business Update webpage) are cut 'n pastes from the call transcript.

    It strikes me this approach, poorly executed because of the cut 'n paste/formatting approach, rather than true, effective and efficient FAQ answers but for fear of their legal shadow I imagine, probably has the goal of focusing existing and prospective shareholders on certain topics management wishes to highlight (I'd normally include the independent directors of the board in also wanting to push a certain [the same] set of topics [an "agenda"], but they're currently asleep at the switch).

    Of note [to me] {my underlined emphasis}:
    • (Provectus CTO Dr. Eric Wachter, PhD on PH-10) "We expect to have the next and presumably final set of data from those patients available to us for review next month. If that looks good, we will certainly push that towards publication. If it looks good, we'll certainly push that towards meeting with FDA to discuss the consummation of the final steps in this development. If that looks good, we will certainly show that to potential corporate partners. We've already discussed this with one of our potential corporate partners, placing them on notice that that data will be coming."
    Updated (11/22/16).1: Provectus' psoriasis Phase 2 study, Randomized Study of PH-10 for Psoriasis, was not powered to be a pivotal trial. The planned or prospective, pivotal psoriasis Phase 3 study [presumably undertaken by PH-10's eventual corporate partner] could have four arms: (i) vehicle (a control), (ii) vehicle + PH-10, (iii) corticosteroid (a topical steroid control) and (iv) corticosteroid + PH-10. 
    Updated (11/22/16).2: p-values (aka statistical significance). Note the following in Provectus' March 2012 press release of its psoriasis Phase 2c study, Announces Top Line Phase 2 Data For PH-10 in Its First Randomized Controlled Psoriasis Study {my bolded and underlined emphasis}:
    "Thirty eight percent of subjects receiving the low dose of PH-10 reported no itching after 28 days compared with 14% of those receiving vehicle (45% of subjects receiving 0.001% Rose Bengal in the earlier study reported no itching after 28 days). PH-10 at 0.002% and 0.005% (along with 0.001% in the prior study) exhibited maximum improvement in Plaque Response Assessment, with the improvements for 0.002% achieving high significance (p < 0.001) after two weeks of treatment..."
    Some slides from associated 2012 collateral material:
    Click to enlarge
    Click to enlarge

    Click to enlarge

    Click to enlarge
    One wonders how much of the historical challenge(s) and delay(s) to arrive at a license transaction have related/relate to, among other things, (i) a solid-to-robust understanding of PH-10's mechanism of action (e.g., there is a clear signal, here is the signal, PH-10 is an immunomodulatory agent in its own right, etc.), (ii) conveying the Rose Bengal-based topical gel's lack of toxicity, and (iii) the rate limiting step(s) of certain humans.
    • (Eric on liver mets from melanoma): "I mentioned that we may look at some other targeted and focused areas of tumor type, such as melanoma metastases to the liver. And the expectation there is that that is potentially a new initiative for us in melanoma to provide a faster way to approval in that it is a disease that there is no apparent standard of care. There is no significant response with current classes of agents. And it's an area where the patient population is in desperate need of new solutions, so scenario where we would not be competing with so many other companies if we are able to show relevance there."
    • (Eric on approval in Australia): "We are collecting data from that expanded access program. We closed enrollment of new patients effective the end of June of this year. We expect the last treatment of patients to occur prior to the end of December of this year. So, we're collecting those data, but we haven't got a complete dataset from that work yet. And whether that will be adequate to support approval in Australia is a question that we will assess as we have a better, more complete dataset. I will point out this is one area where having a subsidiary in Australia may inure to our benefit now. It focuses us more with Australia. It aligns our efforts more closely with TGA in Australia."
    Updated (11/22/16).3: Provectus filed an amended S-1 registration statement today; the last registration statement, also amended, was filed November 1st. I used Diffchecker to compare the two filings. It would appear this new amendment ostensibly conforms the registration statement with the third quarter 10-Q financial and its contents (the original October 5th S-1 filing and the November 1st amendment used the second quarter material).

    Additionally, today's amendment notes a response to the NYSE in regards to the potential delisting of the stock (see below) and a lawsuit filed by Provectus against one of three accounting firms the company employed (see further below).
    Click to enlarge
    Click to enlarge
    Updated (11/22/16).4: The calculation of the number of additional shares and securities to be issued to holders of the August preferred share and warrant fundraising should be completed upon the close of trading tomorrow, November 23rd. InvestorVillage (IV) poster rmgillis appears to have done a nice job undertaking that calculation, generating a figure of approximately 295 million common shares and warrants (on common shares). I had played around with scenarios ranging from 250 million on the low side to 350 million on the high side. See No. 17 under Shareholders are so cute when they try to ask questions (November 12, 2016).

    Assuming shareholders approve an increase in the number of authorized shares to 1 billion (proposal no. 1), let's do a back-of-the-envelope sketch of the possible or potential number of shares (and thus units in the upcoming rights offering where I assume one unit equals one share of common stock and one warrant [on common stock]):
    • 355 million shares outstanding (including, roughly, the original August preferred share and warrants, and dividends) pre-issuance of additional August-related securities,
    • 295 million shares of additional issuance related to the August fundraising (per IV's rmgillis),
    • Equalling about 650 million shares outstanding (the current authorized figure is 400 million, subject to the passing of proposal no. 1), and
    • Leaving up to about 350 million shares or 150 million units for possible or potential use in the rights offering.
    Although I am led to believe the additional securities to be issued to the August preferred stock and warrant holders is restricted [and would have to be registered after some period of time has elapsed, such as at least six months to potentially longer] (some Maxim retail brokers believe otherwise), it's unclear whether both the common stock and warrants (on common stock) to be issued are restricted. It would seem me that both would be restricted (i.e., an early exercised warrant would be exercise into a restricted share of common stock restricted for some period of time thereafter but perhaps with the clock ticking upon issuance of the warrant).
    Updated (11/23/16).5: There are three categories of securities related to the August preferred stock fundraising. First, there were preferred shares (convertible into common stock) and warrants (on common stock) that were issued as part of the offering (i.e., money to the company, preferred shares, and warrants to investors who/that made up the offering). These securities were not restricted. Much if not all of the preferred shares were converted into common stock (there would be no point currently to exercise the warrants because the exercise price is too far out of the money. I imagine the common stock that would be issued upon the exercise of the warrants is freely tradeable too.
    Second, there are the dividends to be/that have been paid, and which have been paid in common stock, which also are freely tradeable, I also imagine, believe and think.
    When I discuss restriction, registration and "144 stock," I only am referring to the additional securities that would (will) be issued upon the calculation of the anti-dilution protection for the August preferred stock fundraising, which would be additional common stock and warrants (on common stock). These, these additional equity securities, I believe are restricted for between 6 months and a year depending on certain variables or parameters that govern the determination of the holding period.
    Only time and disclosure will tell. As I previously noted, folks like pvct-whale (aka pvct in cleveland, PVCT Fixer) who [I believe] are discussing this topic with Maxim retail brokers who themselves are unsure (i.e., they, the brokers, think the additional securities are not restricted, but when pressed admit they do not know for sure).
    Another question I pose to myself is that the dollar value of the rights offering's fundraise has variables of parameters of the number of units available and the eventual price per unit, which would translate into a certain dollar amount (i.e., 150 million units times 4 cents per unit equals $6 million of gross proceeds). What happens if there an oversubscription on a dollar basis? Would the rights offering process account for that and increase the unit price accordingly (assuming the share price does not increase on its own accord because of news and/or more demand than supply prior to pricing)?

    Phase 3 guidance (November 21, 2016)

    In nearly every (if not all) regard(s), Provectus is an event-driven company, as most-to-all biotechnology companies are. Provectus, perhaps, is more so (i.e., more event-driven). Existing and prospective shareholders have to get through the following non-clinical events before the prospects of a runway of clinical events or clinical data catalysts present themselves.

    i. November 23rd: August preferred share & warrant fundraising anti-dilution protection provision calculation (the "additional shares")

    ii. November 28th: Shareholder votes on the proposals of increasing the number of authorized shares, and providing discretion to the board of directors to undertake (if they so deem fit) a reverse split

    iii. By or before November 30th: The issuance of the additional shares. While this "catalyst" probably is minor, the determination of how many shares are available for the rights offering (RO) (see iv. below) would come shortly after ii.

    iv. December: Pricing and closing of the existing investor RO. The requisite shareholder of record date coming presumably would come at the beginning of the month, with the pricing likely occurring towards the end, and management's roadshow occurring in between. See one of Provectus COO and interim CEO Peter Culpepper's slides from the company's November 14th 3Q16 business update call.
    Click to enlarge. Blue dashed arrows are mine
    Once (and, of course, assuming) these non-clinical events are completed (critically, the RO, among others), the focus of the clinical data catalysts comes into view:
    • February 2017: Expanded liver Phase 1 data (APASL 2017, Shanghai, China),
    • 1Q17-: Data, meetings and understanding necessary to generate a PH-10 license,
    • 1Q17-: Data, meetings and understanding necessary to generate a co-development relationship to explore the combination of PV-10 and checkpoint inhibition,
    • June (September) 2017: Phase 1b melanoma combination therapy data (ASCO 2017, Chicago or ESMO 2017, Madrid, Spain), and
    • End of Q2-end of Q3, 2017: Pivotal melanoma Phase 3 interim data readout.
    Regarding the last dataset in the list above, Provectus CTO Dr. Eric Wachter, PhD provided an update (on the November 14th update call) regarding a further delay in schedules (that would include, per prior commentary, clinical trial site start-up, trial patient recruitment, and eventual interim and final data readouts):
    "I must say, however, that the slow uptake in the U.S. and Australia has set back timelines by an additional six to nine months. We have been working diligently all year to move as fast as possible, to open centers as fast as possible. But, we are playing in a very active clinical development environment right now and have done as best as we could."
    This revised guidance would suggest an interim data readout between June and September 2017. See the table below.
    Click to enlarge
    Eric, however, did not explain the hows of the company reaching the interim data readout milestone (e.g., how does the trial arrive at (generate) 81 events?, Is the time setback a function of generating events, and at what rate?, etc.).

    He merely noted on slide 78 (of the November 14th call's accompanying slide presentation) that timelines were set back by six to nine months.
    Click to enlarge.
    Slide 105 indicated time-to-data readout cannot be quantified with certainty.
    Click to enlarge.
    Eric noted the steps delineated on slide numbers 77 and 78 (above) reflected the company’s efforts to ameliorate the impact of a complex development environment to stabilize timelines and accelerate progress. He explained on slide 78 (above) that the situation had improved in the second half of 2016 setting the stage for the expected amelioration and acceleration in 2017.
    Click to enlarge
    Peter later said on the same November 14th call:
    "I don’t believe that we’re trying to communicate guidance on the six to nine months on the interim. The key is, and Eric went through this in detail with all the different sites that are in process of turning up in the different geographies, we need cash through the rights offering to fund that work. The quicker we get up those sites, the quicker we get interim data on top of what we already have, of course, active. So, that’s something to keep in mind that the interim data speed is very much related to the rights offering generating and opening those additional sites." {My underlined emphasis}
    While Eric may be appearing to provide guidance regarding the potential or possible timing of the Phase 3 interim data readout of 2Q/3Q17, and Peter confirmed as much (according to Danish shareholders in attendance) about a month ago (see An Incomplete Story (October 5, 2016) on the blog's Archived VI page), I would imagine Peter is saying above (and may also have articulated the same appropriate commentary in Denmark) that the faster trial sites are up and running, the faster patients may be recruited, the faster events could or would be generated, and thus the faster an interim data readout might be undertaken.

    One has to believe the further six to nine month delay slowed (for the reasons Eric articulated on the call) the uptake of patients in the USA and Australia at the sites noted as recruiting on He noted his mitigation strategy of adding sites in Europe (Germany, Italy, Poland, France) and Latin America (Argentina, Mexico, Brazil); however, I cannot imagine he would be in a position to predict with precision how these EU and LATAM sites were helping to increase the trial's overall enrollment rate until he has experience with these sites.

    It is interesting that, as noted on slide 77, Provectus modified pivotal Phase 3 trial protocol earlier this year specifically to address requirements for Germany.

    Phase 3 execution (November 18, 2016)

    Updated below: 11/19/16 {twice}.

    It would seem, for the time being, that every blog post and news entry should have the same byline, rider or caveat regarding Provectus' board of directors and management team: {the makings of a plan, no credibility, poor decision-making, unable to communicate, inefficient and ineffective execute}.

    Change (augment) the messenger(s), and I believe, the message and, for the most part (with some tweaking, reconsideration, and/or thoughtful, appropriate and consensus-based [to a point] changes), the plan should resonate with existing and prospective investors.

    Now, onto the message behind this news entry...

    Provectus CTO Dr. Eric Wachter, PhD provided an update in his slide deck and prepared remarks (as well as presumed webcast-based answers to questions) on the company's pivotal melanoma Phase 3 trial.
    Click to enlarge
    Click to enlarge
    Click to enlarge.
    I also add another of Eric's slide to the above, particularly related to standard of care (SOC) and de facto SOC.
    Click to enlarge
    In regards to what Eric presented above (re: SOC), also read The Evolving Imlygic (T-Vec) Story, and its Impact on PV-10 (October 26, 2016) below. The 6-9 month additional delay would have suggested a 2Q/3Q17 interim data readout for the Phase 3 trial, which prior to that was a 4Q16/1Q17 readout as a result of an initial 6-month delay, where the contemplated readout period initially and originally was 2Q/3Q16.

    Eric (or Peter) appears to also have communicated time frames too (see the bottom left-hand side of the webcast screen) in, I believe, chronological order:
    "Q: In the presentation, you have indicated that the Phase 3 trial is expected to be pushed out an ADDITIONAL 6 to 9 months. We assume that this is an addition to the 6 additional months that was stated in the 3rd quarter conference call one years ago. Therefore, we would appreciate if you could convert "an additional 6 to 9 months" into a projected date or calendar quarter. 
    A: Q3 2017 is our current projection
    #     #     #     #     # 
    Q: Then when is melanoma P3 interim now expected? 
    A: We are projecting Q2/Q3 2017  
     #     #     #     #     #  
    Q: Have any numerical projections been made by the Company's management as to when "interim data" will be available based on the current rate of patient enrollment? 
    A: We are currently projecting Q2/Q3-2017
    I know Eric's words to some have no credibility (and Peter's words to many more have even less). I assume these replies are or come from Eric, who does not publicly give timing but has missed on timing in the past. They have a certain weight or relevance to me, and I can't say they should or could to anyone else.
    Updated (11/19/16).1: Eric's apparent guidance above (i.e., 2Q/3Q17) are in keeping with Peter's comments to Danish investors in early-October. See An Incomplete Story (October 5, 2016) on the blog's Archived VI page.
    Click to enlarge. Image source
    Finally, related to Eric's comment on the online question portion of the webcast:
    Q: Is there any other triggers for P3 interim analysis other than 81 progression events, if so please specify ? based on current estimate you thing we will get 81 progression event by 3Q2017? 
    A: There are no other triggers
    As Eric has noted previously, the trial's Independent Review Committee (IRC) has discretion, and such discretion relates to an imbalance between the events in each of the control and treatment arms. Discretion, a trigger by any other name...

    Updated (11/19/16).1: I'm led to believe Alan Ross and [some] Trust Intelligence subscribers may have sold substantial portions of their Provectus holdings this past week.

    Updated (11/19/16).2: Provectus filed a supplement to its proxy statement for the upcoming November 28th shareholder meeting and vote on Friday. The supplement is an FAQ of sorts for shareholders. Of note {my underlined emphasis}:
    • "How will the approval of Proposal 1 affect our proposed Rights Offering? On October 5, 2016, we filed a registration statement on Form S-1 (as amended on November 1, 2016) with the SEC to issue subscription rights to our existing common stockholders to purchase units consisting of shares of common stock and warrants to purchase shares of common stock (the “Rights Offering”). We are seeking to raise up to $21 million in gross proceeds from the Rights Offering. If we sell all of the units subject to the Rights Offering, we anticipate having sufficient cash on hand to fund all of our research and development and other capital needs through 2017. With the adoption of Proposal 1, we anticipate having a sufficient number of shares of common stock available to undertake the Rights Offering."
    • "How will the approval of Proposal 2 affect the number of common shares we have outstanding? The Reverse Stock Split will have the effect of decreasing the number of shares of our common stock outstanding because, upon effectiveness of the amendment to our Certificate of Incorporation effecting the Reverse Stock Split, the shares of our common stock outstanding will be combined into a lesser number of shares such that one share of our common stock will be issued for a to-be-specified number of shares, which number shall be equal to or greater than 10 and equal to or less than 50, of outstanding shares of our common stock. The exact ratio will be determined by our Board of Directors prior to the effective time of such amendment. For example, if we had 350 million shares of common stock outstanding at a price of $0.05 per share and effect a 35-for-1 Reverse Stock Split, immediately following the Reverse Stock Split we would have 10 million shares outstanding and each share would be worth $1.75. If a stockholder holds 35,000 shares before the Reverse Stock Split, at a price of $0.05 per share it would be valued at an aggregate of $1,750. Immediately following the Reverse Stock Split, that stockholder would hold 1,000 shares at a price of $1.75 per share, also valued at an aggregate of $1,750."
    • "How will the approval of Proposal 2 affect our listing on the New York Stock Exchange? We anticipate that approval of Proposal 2 would allow us to comply with the continued listing standards of NYSE MKT. Specifically, on October 13, 2016, we received a delisting notice from NYSE MKT related to our common stock price since our shares of common stock have traded below $0.06 per share, which is below the minimum price per share set by NYSE MKT. We have appealed the NYSE MKT decision to commence delisting procedures. If Proposal 2 is approved, we will be able to affect the Reverse Stock Split, which will allow us to increase the price per share of our common stock above the minimum price per share set by NYSE MKT. We are hopeful that effecting the Reverse Stock Split will favorably impact our appeal, but there is no assurance that the NYSE MKT will grant our appeal. The delisting of our stock from the NYSE MKT may adversely affect our ability to, among other things, raise additional financing through the public or private sale of equity securities, may significantly affect the ability of investors to trade our securities and may negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of institutional investor interest and the potential loss of business development opportunities."
    • "How will the approval of Proposal 2 affect our proposed Rights Offering? With the adoption of Proposal 2, we anticipate having a sufficient number of shares of common stock available to undertake the Rights Offering. Additionally, we intend to apply to list the common stock and warrants included as part of the units being offered in the Rights Offering with the NYSE MKT. The NYSE MKT has advised us that NYSE MKT has a minimum price requirement of $0.20 to admit a new warrant for trading on the NYSE MKT. If Proposal 2 is approved and effectuated, we believe that the price of our common stock will increase to an amount such that will allow us to maintain our listing on the NYSE MKT and that our warrants will be priced in excess of the $0.20 minimum price required by NYSE MKT for listing the warrants. There can be no assurance, however, that the price of our common stock will meet the minimum listing standards or that the warrants will meet the minimum listing price of $0.20 to be accepted for listing on NYSE MKT or that a sufficient number of subscription rights will be exercised so that the common stock and warrants will meet the minimum listing criteria to be accepted for listing on NYSE MKT. In addition, if the common stock and warrants are not accepted for listing on the NYSE MKT, we may need to make filings and obtain approval from certain state regulators for the issuance of the common stock and warrants, which could delay and increase the costs of the Rights Offering, and possibly make the Rights Offering unavailable in certain states."
    • "What happens if Proposal 1 is approved and Proposal 2 is NOT approved? If Proposal 2 is not approved, we believe our common stock and warrants will be delisted from the NYSE MKT and the common stock and warrants to be issued in the Rights Offering will not be listed on the NYSE MKT. Consequently, we expect the price of our common stock and warrants to be negatively impacted."
    In truth, most of the supplement is legal CYA for Provectus' board of directors and management as recommended (directed) by the company's outside counsel Baker Donelson, but I thought it was worthwhile noting the above "highlights." The board and management require substantial and substantive assistance, and I believe they are beginning to open themselves up to discussing such.

    Getting back onto the NYSE does seem like a priority for the time being. The timely generation of multiple datasets and transactions (see below) is. Management do less predicting of the future, and do more of writing history.

    It could be unsurprising to see an example of a reverse split figure (i.e., 35-to-1) to explain a particular aspect of the reverse split (RS) to shareholders. It also might be illustrative of the kind the board and management might undertake if given discretion. The RS provides a more straightforward way of fully undertaking the rights offering (RO), as illustrated in the example below. I could envision management's approach and rationale, presumably based on a belief a fully funded 2017 enabling in their view the timely generation of multiple datasets and transactions (e.g., PH-10, combination therapy, GI cancers, geographies, Phase 3, etc.) leading to an ultimate buyout. For the average shareholder with a cost basis of some time ago, participating in the RO versus not participating has a notably stark return difference.
    Click to enlarge.
    Then again, who would trust this board of directors and management team with an RS, specifically, and, generally, to execute their plan credibly with good decisions and communications, efficiently and effectively? Gastrointestinal (November 17, 2016)

    On Provectus' November 14th 3Q16 business update call (webcast here, transcript here), in regards to Eric's liver update, I was struck by two things -- a slide, and then an accumulation of thoughts that coalesced around another slide. First, the update on the expanded liver Phase 1 trial, which he called a "basket" or "all comers" study. This is a topic I want to address again later.
    Click to enlarge.
    Prior to this information, we'd summarize the liver work as:
    Slide #9, Sidoti 2016 (November)
    Now, I'd imagine you would have to summarize it as (based on the information provided by Eric above on the call and in his slide deck):
    Slide #9, Inv€$tival Showcase 2016 (November)
    He noted an update to the July 2015 liver data reporting in Spain and Tokyo would occur in February 2017 in China: the Asian Pacific Association for the Study of the Liver (APASL) (Shanghai).

    Second, I believe the message I heard and read was summarized by one of Eric's ending bullet points, "PV-10 could be a breakthrough for immunologically "cold" tumors." Consider that a melanoma lesion or tumor on (cutaneous) or under (subcutaneous) the skin is immunogenic or "hot." A melanoma metastases on the liver is not as immunogenic, or is [much] colder.

    Generally speaking, gastrointestinal (GI) cancers indicate as cold tumors, where checkpoint inhibition has not had as much or much success to date. You could frame the company's ongoing and planned trials then as:
    Click to enlarge. Slide #16, Inv€$tival Showcase 2016 (November)
    Of course, "planned" above is subject to resource availability, and the company has to get through its contemplated rights offering.

    Australia (November 16, 2016)

    Updated below: 11/17/16.

    1. One of the items worth following up on Provectus' November 14th 3Q16 business update call is whether the company plans to submit for [early] marketing approval in Australia, presumably using but after the compassionate use/expanded access program (special access scheme in Oz) data is ready for submission, together with Australian physician support (doctors there have more input into and involvement in the drug approval process than in the U.S.). PV-10 is de facto standard of care (SOC) for in transit melanoma at two medical institutions there (Princess Alexandra [shown], Peter MacCallum [speculation]).

    One could point to language from the call such as {using Seeking Alpha's transcript}:
    "In addition, we are strengthening ties with Australia's Therapeutic Goods Administration. We've even opened an office in Australia to be able to work more closely with our local collaborators and to function better with regulators and pharmaceutical companies in Asia, it always helps to be in a similar time zone and closer proximity." {Peter Culpepper, Provectus COO and interim CEO}" 
    "Questioner: I got one other quick question please. As far as Australia, I know that PGA accepts compression and used data. Do we have all the necessary data to submit our application for approval with PV-10 or in PH-10 for approval in Australia? 
    Peter: "We are collecting data from the access program, we closed enrolment of new patients effective end of June of this year, we expect the last treatment of the patients to occur prior to the end of December of this year, so we're collecting those data but we haven’t got complete data set from network. 
    Same questioner: To maintain an application or anything like that because we're still working on the data for it? 
    Peter: That's correct and whether that will be adequate to support approval in Australia is a question that we will assess as we have a better and more complete data set, we will point out this is one area, we are having a subsidiary in Australia in healthcare benefit...Our focus is with Australia that aligns our efforts more closely with [TGA] in Australia.?" 
    I see no reason why management cannot come out and clearly and cogently say that is our goal, here's our process and plan, and we'll update you regularly as to our progress on such. Nevertheless, timing on this probably has to flow somewhat concurrently or in parallel with the pivotal melanoma Phase 3 trial (i.e., a 2017 early marketing approval opportunity or possibility).

    2. Institutional. 13F filings (through this writing) for the period ending September 30, 2016 showed:
    • An increase in institutional share holdings of Provectus: 10.6 million shares (up from 8.5 million as at June 30th, or about +24.5% quarter-over-quarter [QoQ]) and 4.3% of shares outstanding* (not a fully diluted figure) (up from 4%), and
    • A decrease in the number of filers to 45 (down from 51).
    * Shares outstanding increased from 212 million (6/30) to 244 million (9/30) (+14.6%).
    Click to enlarge
    Click to enlarge
    Median shares held by reporters/filers increased to 20,000 (from 18,824).
    Click to enlarge
    Updated (11/17/16). 3. Happy Happy Joy Joy. The fifth anniversary of this blog was yesterday, November 16th. What a crazy journey! Over that time, the blog has received (per Google Analytics, and not the widget in the bottom right of the blog's main page) 81.5K unique visitors, 470K visits and 1.1 million pageviews from 160 countries, all 50 US states (and the District of Columbia), and 6,541 U.S. and international cities.

    Totals below are sessions (visits), pageviews and users (unique visitors). Averages below are pages per session, average session duration, bounce rate, and % new sessions.
    Click to enlarge.
    Top visiting countries and cities over the five years are below:
    Click to enlarge
    Click to enlarge
    Pages per session, bounce rate, and average session duration are below. "Random" benchmark metrics are below.
    Click to enlarge
    For more than a year (August 2015), pages per session have hovered around 3. The unofficial industry standard apparently is 2 pages per session.
    Click to enlarge
    For more than a year (August 2015), bounce rates have been 13-20%. Unusually good bounce rates apparently are 25-30%.
    Click to enlarge
    The industry standard for average session duration is 2-3 minutes. The blog has averaged durations in the low 2-minute range (last twelve months: 2:12).

    Pancreatic adenocarcinoma (November 14, 2016)

    Updated below: 11/18/16.

    1. Provectus issued a press released further describing Moffitt Cancer Center's murine model work (a poster presented at SITC) using PV-10 as a monotherapy, and in combination with systemic chemotherapy gemcitabine, Announces Poster Presentation on PV-10 at Society for Immunotherapy of Cancer 2016 Annual Meeting (and filed an associated 8-K). Of note [to me], company CTO Dr. Eric Wachter, PhD's attributed quote:
    "The work reported by Pilon-Thomas and colleagues shows that PV-10 has therapeutic activity in murine models of pancreatic cancer, and that this is augmented when intralesional PV-10 is combined with systemic gemcitabine (GEM), a standard chemotherapeutic agent used to treat this disease. Supporting this observation, their poster showed that PV-10 elicited interferon-gamma production, a hallmark of the induction of an anti-tumor immune response, along with regression of uninjected bystander tumors. They also showed that myeloid derived suppressor cells (MDSC) decreased when GEM was used alone or in combination with PV-10. Since MDSC have an inhibitory effect on a number of immune effector cells, including CD8+ T cells, dendritic cells and NK T cells, the apparent combination effect could result from reduced immune suppression by GEM coupled with immunologic stimulation by PV-10. PV-10 has previously been shown to produce tumor-specific anti-tumor immune responses in melanoma and colorectal carcinoma that includes activation of CD8+ T cells." {my underlined emphasis}
    Under Non-inflamed (excluded) (October 21, 2016) below I had highlighted Moffitt's prior work with the combination of dendritic cells and gemcitabine:
    "Dendritic Cell Immunotherapy Combined with Gemcitabine Chemotherapy Enhances Survival in a Murine Model of Pancreatic Carcinoma," Ghansah et al., Cancer Immunol Immunother. 2013 Jun; 62(6): 1083–1091: "Pancreatic cancer is an extremely aggressive malignancy with a dismal prognosis. Cancer patients and tumor-bearing mice have multiple immunoregulatory subsets including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSC) that may limit the effectiveness of anti-tumor immunotherapies for pancreatic cancer. It is possible that modulating these subsets will enhance anti-tumor immunity."
    Takeaways: Albeit murine model work, more evidence PV-10 is an immunotherapy, and capable of generating additive or better responses in combination with other therapies and therapeutics.

    2. I am led to believe the additional securities to issued (after the appropriate calculation on November 23rd; likely prior to or on November 30th) under the August preferred stock & warrant offering (undertaken for Provectus by Maxim) for its anti-dilution protection are "144 stock." That is, they are restricted for some period of time (i.e., 6-12 months depending on certain parameters), and presumably cannot and would not be sold prior to Provectus' contemplated rights offering.
    Updated (11/18/16): What are the chances that Investor Village poster pvct-whale (aka pvct in cleveland, PVCT Fixer) has Dan Ballestra as his retail rep at Maxim Group? If so (and it doesn't really matter who the rep is as long as it is a retail one), it would explain a lot, or a little (as in little knowledge), as the case may be.
    3. I'll provide comments on Provectus' 3Q16 business update call today in a blog post in due course.

    Shareholders are so cute when they try to ask questions (November 12, 2016)

    Updated below: 11/13/16.

    Image source
    Questions (among others, and other items) I have asked Provectus' CTO Dr. Eric Wachter, PhD to address on Monday's 3Q16 business update conference call:
    • 1. Phase 3 melanoma
      • Visible/transparent and "invisible"/opaque analysis triggers
      • Status of adding additional sites, and why (e.g., enrollment, in-country registration, etc.)
      • Status of enrollment
      • Status of NDA preparation
      • How PV-10, if approved, fits into NCCN guidelines (e.g., first line, SOC, etc.) [not necessarily where]
      • Initial addressable market for PV-10
      • Potential post-marketing commitments or requirements, if any/applicable
      • Tracking overall survival (i.e., the whys, whats and hows)
      • Stratification of data, if relevant/applicable (e.g., by comparator, by geography, etc.)
      • Recent changes to the protocol (ESMO 2016), timing of changes on, implementation at existing and prospective sites
      • Biggest historical and/or ongoing challenge(s) to running the trial
      • Import of comparing PV-10 to T-Vec (and chemo to T-Vec)
    • 2. Phase 1b melanoma combo w/ pembro
      • Status of program (e.g., enrollment, completion of Phase 1b portion?, advanced to Phase 2?, etc.)
      • Timing and venue of interim data presentation
      • Relevancy of additional clinical data sets (e.g., immune biomarkers, etc.)
      • Uniqueness and impact of concurrently running the P3 trial (all disease treated) and the P1b trial (some disease treated; induce and boost an immune response)
      • Status of adding additional sites, and why (e.g., enrollment, etc.)
      • Plans, if any, of applying for an accelerated pathway to approval
    • 3. Phase 1 liver
      • Status of program (e.g., enrollment, enrollment by expansion cohort, integration of or continuation of or separate Phase 1b/2 work)
      • Thesis(es), timing and venue of data presentations and/or publications
      • Initial pathway to approval (e.g., potential label description, liver cancer analog to PV-10 locally advanced cutaneous melanoma)
      • Plans, if any, of applying for an accelerated pathway to approval
      • Relevancy of additional clinical data sets (e.g., immune biomarkers, etc.)
      • Biggest historical and/or ongoing challenge(s) to advancing program
    • 4. Other cancer indications (clinical)
      • Potential plans for moving other indications/tumor types to the clinic (e.g., PV-10 as a monotherapy and/or in combination with chemotherapy [gemzar] for pancreatic cancer, etc.)
      • Thesis(es), timing and venue of data presentations and/or publications
    • 5. Preclinical research (oncology)
      • Status of program(s)
      • Thesis(es), timing and venue of data presentations and/or publications
      • Observation(s) of third parties using off-the-shelf Rose Bengal and/or Provectus-supplied PV-10 (e.g., widespread?, historical?, etc.)
    • 6. PH-10
      • Status of program (e.g., EOP2 meeting, prospective psoriasis P3 trial design, atopic dermatitis, etc.)
      • Phase 2 mechanism of action data results
      • Initial pathway to approval (e.g., potential label description, PH-10 analog to PV-10 locally advanced cutaneous melanoma)
      • Timing and venue of data presentations and/or publications
      • Biggest historical and/or ongoing challenge(s) to advancing program
    If you feel I have missed something, please let me know so I may ask Eric.

    Updated (11/13/16): "As some people (shareholders) appear to believe, help us understand if you have made any decision(s) not to release relevant data and progress made and how, if any, has such a decision(s) to follow this path benefited the company and its chance for success?" {question source}

    Stuck in the middle with you (November 10, 2016)

    Updated below: 11/10/16, 11/11/16 (twice) and 11/12/16.

    1. Provectus filed the company's third quarter 10-Q yesterday. As I noted under Don't have enough details to do so before (November 6, 2016) below, I wanted to know/see/read (among other things) quarter financials, cash and cash equivalents, average monthly cash burn, all asset and liability line items on the balance sheet in general (or as a rule), and management's discussion and analysis (MD&A).

    There are various relevant specifics of one sort or another, but generally speaking it was vanilla in most regards. What could be less vanilla should be Provectus CTO Dr. Eric Wachter, PhD's comments on the upcoming Monday (14th) 3Q16 business update call.

    Cash and cash equivalents at September 30th was $5.2 million, which was in line with what I forecasted or expected (at the risk of sounding too serious or equity analyst-y). Average monthly cash burn was $1.7 million ($1.67), which was roughly as (slightly higher than) expected ($1.6). MD&A was generally uninformative.

    2. Eric's prepared remarks on Monday's investor conference call could be accompanied by a slide deck that could provide more breadth and depth to said remarks. I have been pushing the company to communicate better (other shareholders have been too), and suggested the aforementioned slide deck approach

    3. Watercooler-ing
    Click to enlarge. Tweet image source
    Notable comment from Idera's presentation: "Anti-PD-1 established as standard of care, with no clear consensus on treatment after failure"

    4. More watercooler:
    Click to enlarge. Tweet image source
    Clowns to the left of me, jokers to the right.

    Updated (11/10/16).1: 5. If I'm Provectus' Chairman Al E. Smith IV, I begin to demonstrate leadership by encouraging the company's COO and interim CEO to have an twelve word limit on Monday's business update call: e.g., "Thank you Michael. Let me now turn the call over to Eric."

    6. More seriously, I begin to demonstrate leadership by attending or joining the call, even if I don't plan to or do not say anything other than, "Good afternoon." It's the small things...

    7. If I am independent board member, surely I must ask myself, and ask fellow independent directors: how much time are we really spending doing our jobs, and is our time (and the quality of it) commensurate with our cash compensation?
    Click to enlarge
    8. Are Koe, McMasters and Smith worth $2,600 to $3,300 an hour? I'm gonna say.... Provectus' CFO John Glass is paid $100 per hour (plus a per diem).

    9. If I am an independent director, I would (among other things, and in no particular order):
    • Have a frank conversation about salaries with "President" Dr. Tim Scott, PhD, Peter and Eric, while at the same time balancing that conversation with one about success-based future compensation,
    • Have Peter and Mr. Glass prepare a rolling 6- and 12-month burn rate projection (which would be updated biweekly to monthly), intensely review, critique and potentially modify/add to/change to it, and then have them implement said MACs,
    • Work competently, diligently and passionately with Eric to connect the clinical side of the company with its financial side, and persistently explain to him the importance and benefits of that connection to both sides,
    • Review the folks and firms on Peter's vendor list, and then...,
    • Have a new sub-committee of the board review and approve any and all expenditures over, say, $5,000 for some period of time. If I, as a lower paid (i.e., $ per hour) director, now spend more time with/on the company, I should have considerably more time to pay attention to matters,
    • Attend business update calls (with no plans to speak or answer questions), and,
    • Do certain other stuff...
    Updated (11/11/16).2: 10. Recent visitors to the blog have included The New York Times (new visitor; Current News) and Apollo Global Management (return visitor; Archived News VI, Disclosures).

    11. Our special proxy vote:
    Click to enlarge. Illustrative ballot with voting positions pictured above.
    12. Rationale, Proposal #1: FOR; to (i) meet the share issuance requirements of the August preferred stock and warrant fundraising, and (ii) have shares (for issuance) to subsequently raise funds (i.e., the rights offering).

    13. Rationale, Proposal #2: AGAINST; to prevent an inefficient, ineffective, inert, inept and inane group of independent directors from obtaining the discretion to discuss -- let alone implement -- a reverse split, because it should be abundantly clear they (i) know little to nothing of finance and the capital markets (among a lengthy list of various other topics and subject matter), (ii) practice weak corporate governance, and (iii) employ poor process in much if not all of their processes (such as these "processes" are).

    Updated (11/12/16).4: 14. If the independent directors are, um, too "shy" to stand-up to/oversee either or both of Peter and Eric, maybe they should ask for help...

    15. Speaking of asking for help, did any of the directors, insiders or outsiders, ask questions of the Maxim representative regarding the potential anti-dilution provision's impact on share issuance? Did Maxim provide guidance on the topic? Did Peter provide such information to the board? Did CFO John Glass do the calculation? Did Baker Donelson staff undertake the calculation and provide guidance to the board? More than likely, no, no, no, no, and no.

    Imagine, all of these folks and others the independent directors have the company pay to provide them such excellent, competent, thoughtful work products. Would not one or more of the directors think to turn to someone(s) else for a better outcome?

    16. It's interesting to read one of Peter's entourage speak for him in the context of Eric (InvestorVillage poster STARLIGHT66) (I jest of course):
    "2 guys baking a cake. One prepares all the ingredients and mixes it all together. The other just puts it in oven and tells all the guests to expect a delicious cake for dessert. The cake turns out disgusting. Who do you blame?"
    You blame both. You also blame the four other guys also baking the cake (the independent directors). The analogy above does not pass the red face test because there are (i) two guys drawing half a million dollar salaries who could regularly check on the ingredients, the recipe, the baking, etc., (ii) one guy of those two aforementioned ones who formerly used to buy the ingredients (you'd imagine he would have learned to check on the ingredients, at a minimum), (iii) three guys who might be walking around the kitchen from time to time and pass by the oven -- why wouldn't they check in with the key baker?, (iv) etc,

    17. My back-of-the-envelope calcs, which I think are in the ballpark (illustrative and representative), for available shares to raise money through the rights offering (without giving benefit or cost to a reverse split):
    Click to enlarge
    Clinical Trial Status Update: Melanoma P1 combo w/ pembro (November 8, 2016)

    PV-10 in Combination With Pembrolizumab for Treatment of Metastatic MelanomaH/t InvestorVillage poster Warlord: Cedars-Sinai Medical Center is now recruiting (fourth of four currently recruiting sites). See update (August 8, 2016) on the blog's Archived News VI page.
    Click to enlarge
    Clinical Trial Status Update: Melanoma P3 (November 7, 2016)

    PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma, Washington University School of Medicine - Dermatology has started recruiting:
    Click to enlarge.
    See Clinical Trial Status Update: Melanoma P3 (October 25, 2016) below. Eight of nine clinical sites listed on now are recruiting.

    Image source
    Don't have enough details to do so before (November 6, 2016)

    Updated below: 11/6/16.

    Emails appear to have been sent to Provectus shareholders (as of the relevant record date) for the upcoming November 28th special meeting to vote on two proposals (i.e., an increase in the number of authorized shares, board of directors discretion for a reverse split).

    While I currently plan to vote our shares for the first proposal and against the second, I expect to wait until just before the Internet voting deadline (11:59 pm EST, November 27th) to do so. Why?
    Click to enlarge
    Because there are some additional details I'd like to gather, see and understand, some of which are not or may not be directly germane to my voting decision, such as but limited to:

    1. November 9th: Provectus' quarter financials (i.e., the calendar quarter ending September 30th), such as (but not limited to) cash and cash equivalents (forecast: >$5.2 million), monthly average cash burn (forecast: $1.6 million), all asset and liability line items on the balance sheet in general (or as a rule), and management's discussion and analysis.

    2. November 12th/13th: Moffitt Cancer Center's SITC 2016 poster "Intralesional injection with rose bengal and systemic chemotherapy induces anti-tumor immunity in a murine model of pancreatic cancer," and what if any press release they might issue and/or media interviews they might give.

    3. November 14th: Provectus' 3Q16 business update conference call

    4. November 23rd: The number of the additional shares to be issued as a result of the anti-dilution protective provisions from the August preferred stock and warrant fundraising.

    5. Other news that may or may not materialize.

    6. The individual and collective amounts of money Provectus management may invest in the rights offering.

    7. The board of directors' conduciveness.

    8. The pricing of the rights offering, if such details are made prior to my voting.

    9. Sharing and/or discussing implementable thoughts about corporate governance, corporate development, and business operations with management and the board (some of which they likely have not thought about or have demonstrated an inability to effectively, competently and/or in a timely manner address and/or execute).

    Am I missing anything?

    Updated (11/6/16): 10. Hopefully included in no. 3 above, the process towards securing, if possible or if all, a license of PH-10. I obviously carefully couched or "caveated" the prior sentence. Despite dermatology potentially being a much larger addressable market than oncology, management's historical "plan" has been to try and license PH-10 (for inflammatory dermatoses) in order to fund the development of PV-10 (oncology, solid tumor cancers). We know how well that worked out... While I think it's fair to criticize the outcome, or lack thereof, I'm not so sure one can criticize the thought process behind it and diminish the challenge of convincing regulatory and industry folks about the lack of toxicity of PH-10.

    Provectus presumably thought it could out-license PH-10 towards the end of 2009 following data from various clinical studies. I believe this consideration was commensurate with mongering about Galderma's interest at the time (early-2010, and before the company fundraised in March). I believe the mongering described an all-backend deal (i.e., not upfront payment) that probably did not progress beyond words (vis a vis paper [i.e., a term sheet]). In late-2010 Provectus hired dermatology advisor Dr. Seth Orlow, MD, PhD.

    The company's S-1/A described a use of funds for the rights offering notably absent of PH-10:
    "We intend to use approximately $15 million of the net proceeds from this Rights Offering for clinical development, including approximately $5 million to complete our ongoing phase 3 clinical trial of PV-10 to treat locally advanced cutaneous melanoma, approximately $5 million to complete our phase 1b/2 combination study of PV-10 and Merck’s KEYTRUDA in late stage melanoma and approximately $5 million to complete our phase 1b/2 study of PV-10 in liver cancer, and we intend to use the remaining net proceeds for working capital and general corporate purposes. If we sell all of the Units subject to the Rights Offering, we will have sufficient cash on hand to fund all of our research and development and other capital needs through 2017." {my underlined emphasis}
    What gives...does PH-10 not require funds for "completion" of one sort or another? My sense is, whether fair or not, whether ultimately successful or not, management probably expects to license PH-10 without additional study (but perhaps some additional expense). A key question of course would be "when:" by the end of the year, or sometime in 2017?

    Expansiveness (November 4, 2016)

    Depending on whether Provectus' expanded Phase 1 study of PV-10 for cancer of the liver has treated patients already on a course of targeted therapy sorafenib (expansion cohort 2.2), the company has shown and/or is generating preclinical and clinical combination therapy in multiple tumor types/solid tumor cancer indications of PV-10 plus chemotherapy, radiation (radiotherapy), checkpoint inhibition, and [potentially] targeted therapy.

    Click to enlarge.
    There would appear to be "expansiveness" in, about or surrounding the combinatorics of PV-10.

    This expansiveness should suggest the general pursuit of harnessing the immune system against cancer is a major step forward, at least as it is now being pursued. There have several mentions at recent medical (oncology) conferences that disease burden may play a role in immune response. In a field that models immune suppression and immune exhaustion, immune capacity also is important and is precisely what tumor-infiltrating lymphocyte (TIL) therapy addresses -- magnifying the capacity of the immune system.

    PV-10 clearly reduces tumor burden, and clearly educates and incites the immune system.

    Perhaps PV-10 also exhibits "expansiveness" by functioning synergistically with other immunotherapies and/or by removing a powerful deterrent to the effectiveness of non-immunotherapies.

    Provectus' CTO Dr. Eric Wachter, PhD is going to have to bring it, and bring it expansively, on November 14th when he hopefully would provide a comprehensive technical/technology overview presentation as part of the company's 3Q16 business update.

    Ablation (November 3, 2016)

    H/t InvestorVillage poster canis_star: A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC), sponsored by the National Cancer Institute

    The ablative (ablation) therapies include:
    Neither TACE nor RFA is likely to provoke much of a T cell response. TACE is a weak immunomodulatory therapy and RFA is likely to denature tumor antigens. Cryoablation might be a better candidate; however, it is relatively uncommon in the West.

    Nevertheless, the approach above (of ablation plus multi-checkpoint inhibition) is in keeping with the growing realization in the biopharmaceutical industry that it will take more than just checkpoint inhibition to achieve the next step forward in oncology.

    Updates Galore! (November 1, 2016)

    Updated below: 11/2/16 and 11/3/16.

    1. Clinical trial status update: Expanded Phase 1 liver, A Study to Assess PV-10 Chemoablation of Cancer of the Liver
    • Overall anticipated enrollment was increased (by 24) from 42 to 66,
    • Enrollment in Expansion Cohort 1 (EC1) was increased (by the above 24) from up to 24 to up to 48. Patients in EC1 have cancers metastatic to the liver or recurrent hepatocellular carcinoma (HCC) (as opposed to patients in EC2 who are/were on a course of sorafenib), and
    • EC1 treatment protocol was revised such that if a patient (with liver cancer) had more than one injectable tumor, he or she would be eligible for/could receive additional PV-10 treatment of additional injectable tumors 28 days to 120 days between different tumor injections. Such additional treatment could be repeated until all injectable tumors received PV-10.
    Click to enlarge. Image source
    Takeaway: The number 24, combined with the changes to the treatment approach (i.e., potentially permitting multiple liver tumors to be treated with PV-10) suggest [to me at least] the expanded Phase 1 liver trial has become, is or will be the Phase 1b study. See, for example, a Google search of "Phase 1b" and "24 patients."

    3. During Provectus' COO and interim CEO Peter Culpepper's presentation at Sidoti's Fall 2016 Emerging Growth Conference, he said the chemotherapy in Moffitt's murine model combination work of PV-10 and chemotherapy for pancreatic cancer was gemcitabine (Gemzar). See September 26, 2016 blog post SITC 2016: Intralesional injection with Rose Bengal and systemic chemotherapy induces anti-tumor immunity in a murine model of pancreatic cancer.

    4. Peter also said there were hundreds of halogenated xanthenes. Halogens on the periodic table include elements like fluorine, chlorine, bromine, iodine. Potential relatives of Rose Bengal numbering in the hundreds could suggest a vast number of ways to tweak the base molecules. I have asked the company for clarification.

    5. Provectus filed its amended S-1 for the existing investor rights offering today. The original, initial or preliminary S-1 is here.

    6. The proxy meeting date by which to vote on two proposals (an increase in the number of authorized shares, providing discretion to the board to effect a reverse split) has been moved from November 21st to November 28th. It originally or initially was scheduled for November 14th in the initial or original S-1; the 3Q16 business update conference call is on November 14th.

    7. I needed to read the S-1/A to remind myself the range of contemplated reverse splits was 1-to-10 (not 1-to-20) to 1-to-50. It affects the math of some risk management calculations.

    8. Per the S-1/A, use of proceeds appears to be:
    "We intend to use approximately $15 million of the net proceeds from the exercise of Subscription Rights for clinical development, including approximately $5 million to complete our ongoing phase 3 clinical trial of PV-10 to treat locally advanced cutaneous melanoma, approximately $5 million to complete our phase 1b/2 combination study of PV-10 and Merck’s KEYTRUDA in late stage melanoma and approximately $5 million to complete our phase 1b/2 study of PV-10 in liver cancer, and we intend to use the remaining net proceeds for working capital and general corporate purposes."
    Those are "round numbers," eh? Placeholders...

    9. First in the S-1 (I was reminded of it reading the S-1/A), and perhaps of interest only to me, but:
    "We plan to commence the phase 1b/2 liver study in late 2016 or early 2017. This study has potential for generating sufficient data to support expedited approval under one or more FDA programs. 
    In July 2015, data were presented at two conferences that show our progress to date on the treatment of hepatocellular carcinoma and cancers metastatic to the liver. We made a poster presentation at the ESMO 17th World Congress on Gastrointestinal Cancer (ESMO GI) in Barcelona at the beginning of July, and detailed data from our relevant Phase 1 study of PV-10. The main conclusion was that preliminary evidence of efficacy in treatment of cancers of the liver with PV-10 was observed. That same week, Dr. Sanjiv Agarwala presented the data in poster form at the 6th Asia-Pacific Primary Liver Cancer Expert Meeting, APPLE 2015, in Osaka, Japan. Both of these posters can be found on our website What these data show is that PV-10 affects cancers of the liver in much the same way it does melanoma. More work has to be done, but we believe that these results support rapidly development of PV-10 in a randomized Phase 2 study after dosing with standard of care is optimized. This is the Phase 1b/2 study we also refer to above." {my underlined emphasis}
    10. Dr. Allison's symptoms, see TZ 2 (October 31, 2016) below, are his realization(s) it will take more than just checkpoint inhibition to achieve the next step forward in oncology.

    11. October blog readership stats
    Click to enlarge.
    Click to enlarge
    Click to enlarge
    Click to enlarge.
    Updated (11/2/16).1: 12. The final proxy statement (Schedule 14a) (for the special meeting and vote no. 6 above) was filed by Provectus today. Notably:
    Click to enlarge. page 9, image source
    I also did a comparison of the final proxy with the revised preliminary proxy filed on October 21st (using Text Compare!).

    13. This is what happens when a class of drug/drug compounds gets approved for the first time...lots of me toos (with the idea and hope that they improve on the first-in-class [T-Vec], whether by construction or administration or both).

    14. Speaking of no. 12, how are party planner and comedian Al Smith (and other independent directors), Maxim Group (as placement agent/book runner) and Baker Donelson not subject to some liability for having opined on, authorized and then undertaken a stock transaction with insufficient shares? Did none of them do the calculations and projections (related to the anti-dilution protections of the August preferred stock transaction) illustrated in no. 12 above?
    Updated (11/3/16).2: Speaking of Maxim, if the firm plays strategic advisory and valuation roles (among others), how high is the Chinese wall between various groups and departments at the investment bank? Given the potentially questionable circumstances around the August preferred stock and warrant offering, is there pause to be given?
    Click to enlarge. page 68, image source
     "In November 2008, we entered into an agreement with Maxim Group LLC, under which Maxim Group LLC provides valuation, strategic advisory and other similar services to use and receives $7,500 a month. The agreement is a month-to-month arrangement and may be terminated by us at any time upon 30 days’ notice. From time to time in the ordinary course of their respective business, the placement agent and its affiliates have and may in the future engage in commercial banking or investment banking transactions with us and our affiliates. We have no present arrangements with the placement agent for any such transactions."
    TZ 2 (October 31, 2016)

    1. Moffitt Cancer Center updated its PV-10-related study (active, not recruiting) on, Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study, changing the estimated study completion date from December 2016 to April 2017. Why does Moffitt keep pushing out its completion date, and what ultimately do they wish to communicate?

    Writing the clinical study report (CSR) is a very detail-heavy process. Since the feasibility study falls under Provectus' investigational new drug (IND) application, its CSR requires more detail than Moffitt otherwise might require because the company's CSRs comply with International Council for Harmonisation (ICH) standards, meaning all data must be very carefully validated and documented (these documents generally exceed a thousand pages). I am led to believe Provectus is devoting resources to the extent possible to help Moffitt complete this documentation. Until the CSR is final, the feasibility study would remain open (it would not be closed until the CSR is submitted to the institutional review board [IRB]).

    How relevant or important is the CSR itself, setting aside the knowledge delivered via Moffitt's paper on mechanism of action (MOA), to actual and potential Provectus stakeholders (e.g., a global regulatory agency like the FDA, a prospective purchaser of the company)?

    The CSR is a requirement to complete the study. Additionally, regulators and potential partners like things in neat, final packages. The most important aspect of a CSR, from a regulatory perspective, is thorough documentation of adverse events because these are considered in eventual risk-benefit decisions. The top line results already were reported (in Moffitt's MOA paper "Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1"); it can be expected, however, that biological specimens would be further analyzed as additional biomarkers are identified.

    2. Is it appropriate to consider PV-10 agnostic to disease presentation and, presumably, solid tumor cancer? What preclinical or clinical basis, or reasonable extrapolation therefrom, could one approach considering this in order to properly assert, even with the word "potentially", agnosticism (as in potentially agnostic)?

    The slide below is one that Provectus CTO Dr. Eric Wachter, PhD uses regularly in his PV-10-related briefings and discussion.
    Click to enlarge.
    Since there can be significant differences from model to bona fide (genuine) tumor, it is a stretch, so far, to say PV-10 is agnostic to indication. For instance, PV-10 may work against a tumor type established in the flank of a mouse, but not against that tumor type in a target organ. It also is true PV-10 may work better in patients than in models. A good example of this is in melanoma, where the murine models generally were much less responsive than in patients. This is the importance of clinical trials. Part of the improvement of response in patients (versus mice) may be due to the inevitability of immunologic response to PV-10 ablation, which which is a very interesting corollary to agnosticism to tumor type, since it suggests an immunologic response if tumor tissue can be ablated by/with PV-10.

    Immunotherapy has been a game changer in oncology, improving survival and providing long, durable responses in melanoma, lung, head and neck cancer, and others. 
    The success of immunotherapies in those cancers—which are likely seeing a better rate of response due to their high mutational burden—is now paving the way for what are known as “cold” tumors, those that don’t have a heavy mutational burden or significant T-cell infiltration, said James Allison, PhD. 
    “There is enough progress being made across the board that I think we can start thinking about some of the colder tumors responding if we just keep studying and making rational combination decisions,” said Allison, professor and chair of Immunology at MD Anderson Cancer Center. “As we understand this better, we can rationally put two things together that won’t just duplicate or cancel each other out, but will do different things that can at least be additive, if not synergistic.”
    Dr. Allison's comments are consistent with St. Luke's Dr. Sanjov Agarwala, MD's argument that the medical community should "make the tumor your friend," and arguments made by neoadjuvant advocates that immune activation prior to definitive treatment (e.g., excision) is the way to go. There are interesting mega-trends afoot, and they are fascinating to watch.

    In other news, the maturation in immuno-oncology (IO) has become a pandemic, with Dr. Allison clearly showing symptoms in the article above. This was evident in New York City in March and Rome in April, and it finally, clearly, has reached the far corners of the globe. I'm sure Dr. Wachter earnestly hopes shareholders can keep their collective heads together long enough to benefit from this huge phenomenon, now that oncologists realize current IO is not mission accomplished.

    Tying up this thesis, an identical trend occurred in 2009-12 when the industry thought vemurafenib (Zelboraf) [Plexxikon/ Daiichi-Sankyo, Genentech] had "solved" melanoma. When, in reality, the progress was two steps forward, one step back. Let's hope Provectus is ready to catch the next wave (apologies for the mixed metaphor).

    The Evolving Imlygic (T-Vec) Story, and its Impact on PV-10 (October 26, 2016)

    Updated below: 10/27/16.

    Intralesional (IL) drug and oncolytic virus (OV) talimogene laherparepvec (T-Vec) (Imlygic) — broadly labelled by IL key opinion leaders (KOLs), such as Dr. Sanjiv Agarwala, Dr. Merrick Ross and Dr. Robert Andtbacka, as oncolytic immunotherapy ("OI") so as to include PV-10 in this category — is an approved drug for limited monotherapeutic use in metastatic melanoma. Like PV-10, T-Vec also has drawn attention for use in combination therapy as a stimulatory agent and agonist for its potential to induce an immune response that a checkpoint inhibitor then might/would potentially boost

    T-Vec is, for all intents and purposes, the only IL competitor of PV-10 for monotherapy use in melanoma. It was of course the first IL agent to be approved, in October 2015. Imlygic, however, was well known and ultimately has turned out to be a bad product (e.g., supply chain complexity, biosafety restrictions) with limited global commercial availability (e.g., USA, Germany).

    Provectus rolled out its pivotal melanoma Phase 3 trial program on April 9, 2015 in NYC by describing the company's (CTO Dr. Eric Wachter, PhD's) goals for the study, establishing expectations, for what was already going to be a challenging study for which to recruit, of 25 U.S. trial sites, 10 Australian ones, and a few sites in selected other geographies (countries). See Panelling (April 9, 2015) and Share (April 9, 2015) on the blog's Archived News III page. The company initiated the trial and began recruiting at one site (St. Luke's) later than month.

    Just a few weeks later (April 29, 2015), and six months before its eventual approval, T-Vec underwent an FDA advisory committee that established its initial pathway to approval. See April 29, 2015 blog post The first guy through the wall.

    Provectus management (Eric) is certain to confirm a second delay to the expected timing of the Phase 3 study's interim assessment or data readout on the company's November 14th 3Q16 business update conference call. The first delay of 6 months ["we are approximately six months behind schedule"] was discussed on the May 10th 1Q16 business update call.

    I would imagine the second delay, as has been discussed here on the blog -- see An Incomplete Story (October 5, 2016) on the blog's Archived News VI page -- should be another 6 months. What was initially expected to be a June/July 2016 readout now could be a June/July 2017 one; earlier for optimists, later for pessimists [and realists?].

    T-Vec's approval has cost Provectus at least a year. On the one hand, the approval helped bring recognition to the category of IL/OI agents. On the other hand, T-Vec appears to have made it very challenging and not the least bit complicated for Provectus to run its pivotal Phase 3 trial of PV-10 as a monotherapy for the treatment of locally advanced cutaneous melanoma.

    As Eric previously has noted, he is continually adjusting study execution to address actual or perceived changes in melanoma standard of care (SOC) in the U.S. and around the world. Why? Because, I believe, a successful PV-10 Phase 3 trial positions the Rose Bengal-based investigational drug as the global SOC for Stage IIIB-IV M1a disease (as appropriate) (based on NCCN guidelines). Provectus' pivotal (registration) Phase 3 trial after all is a global study, and in some or many respects the first of its kind.

    I fully expect him to acknowledge on the November 14th business update call that a major source of change, and thus delay, has been caused by the approval of Imlygic. I hope he will explain it clearly and cogently to shareholders, and place the delay in the context of where the company and the trial stand, and where they are positioned going forward.
    Updated (10/27/16): See illustration below (Figure 1).
    Click to enlarge. Figure 1
    Comparators (i.e., drugs used in control arms) generally are approved medicines for the reason that use of anything unapproved requires the trial sponsor to garner competent authority and institutional review board (IRB) approval for multiple drugs — that is, essentially filing an investigational new drug (IND) application for both the drug under investigation (i.e., the treatment arm) and, if applicable, the unapproved comparator (the control arm; for ease, call it drug or drug compound ABC).

    If ABC is approved in one country but not another, it is not possible to source ABC in the approved country and supply it to the unapproved country without triggering a regulatory nightmare in the unapproved country. In the case of T-Vec/Imlygic, the necessary technical information is not available outside of Amgen to file such an IND [that is, an IND for the purposes of using ABC or T-Vec in a global pivotal trial of PV-10] (e.g., manufacturing, stability, safety and efficacy data, etc.).

    Thus, I believe, we also should hear Eric say Provectus has had to work with what is available, where it has been and is available to progress the company's pivotal trial.

    U.S.A. In the US, T-Vec's approval has led to commercial launch of the drug, and its availability as a comparator in/for Provectus' pivotal melanoma Phase 3 trial. It does not appear, however, that Imlygic is universally used here. As such, I believe it has been necessary for Eric to find sites that not only can use it but that have sufficient patient numbers to justify site operations.

    Australia. It does not appear to me that approval of Imlygic has led to routine commercial availability here. Amgen and T-Vec have yet to garner reimbursement from the Australian government. It also appears T-Vec only is available as clinical trial supply, when supplied by Amgen for Amgen studies. The fact T-Vec hypothetically is available appears to have changed the SOC in the opinion of some to many Australian clinicians. They may consider the other comparator in the pivotal trial like chemotherapy obsolete, despite the fact they cannot offer the de facto replacement to their patients.

    The European Union (EU). While Imlygic has been approved in the EU, it appears to only be commercially available in Germany. This outcome should be fortunate for Provectus because the Germans have been at the forefront of IL therapies for at least 20 years. The company's Phase 3 study fits well there in terms of SOC (i.e., de facto and bona fide). This also is presumably why Amgen invested its resources to launch the product in Germany. France, Italy and Poland, where I believe Provectus is considering other study sites, are somewhat different stories. I imagine we should hear Eric say the company is taking measures to open sites in at least some of these EU countries (and maybe others). If Amgen fails to launch T-Vec in these countries, the situation of perceived SOC (and its potential impact on the Phase 3 study) should be very similar to that of Australia's.

    The Rest of the World. Imlygic is not approved here, and there is no foreseeable commercial availability of the drug. Places like Russia, China, Mexico and Argentina, while they each pose different but non-trivial logistic and regulatory challenges, should be appropriate and fertile for matching investigators and patients in Provectus' pivotal study design.

    Takeaways & Questions:
    • T-Vec's approval probably has cost Provectus at least a year in terms of meeting its timeline for achieving interim and final assessments for safety and efficacy.
    • I am far less concerned about Eric's pivotal trial design (and the likelihood of PV-10 winning it, and beating both chemotherapy and oncolytic viral therapy in doing so) than I am wondering more so about when it will win (i.e., when could the interim assessment be).
    • How many events, in either the control arm or the treatment arm or both, (or what range of events) are required to trigger an interim assessment?
    • Is trial recruitment now a question of enrollment per site or the number of sites above some reasonable threshold?
    • I have no doubt Provectus' Phase 3 registration study will continue to be dynamic, and more than likely require more and continual recalibration of efforts during its execution.
    Clinical Trial Status Update: Melanoma P3 (October 25, 2016)

    Updated below: 10/25/16 {thrice} and 10/26/16.

    PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma, new site:
    Click to enlarge
    Updated (10/25/16).2: Dr. Cornelius' involvement in clinical trials may be found here. Her co-authorship on biomedical literature may be found here.
    Updated (10/26/16).3: In the US, Provectus' Phase 3 trial population usually is seen by surgical oncologists (e.g., MD Anderson's Dr. Merrick Ross, MD, Huntsman Cancer Institute's Dr. Robert Andtbacka, MD); however, there is overlap with dermatologists (e.g., Cornelius above) and medical oncologists (e.g., St. Luke's Dr. Sanjiv Agarwala, MD).  This reality is reflected in the specialty of the study's principal investigators (PIs). In general, PIs are selected to have a referral network to allow them to recruit patients that are outside their core patients.
    Updated (10/25/16).1: Sharp Memorial also has begun recruiting, after being added to the study's page nearly a year ago.
    Click to enlarge.
    There are a total of 7 sites recruiting now.

    Updated (10/25/16).2: As we stand now, I'm going to guess ("forecast") Provectus may/could recruit and treat 20-30 patients through the end of 2016.
    Click to enlarge.
    I think the patient number target or goal is between 60 and ~80 (81), with the risks being (i) an "expected" outcome of many more events in the control arm than the treatment arm and (ii) overoptimism on the number of events required (<27) to trigger an interim analysis.

    Assuming (a) the further refinement of the protocol (mentioned at ESMO 2016) is in place by year-end, (b) sites 8 and 9 are recruiting by then and (c) Huntsman Cancer Institute and MD Anderson are much more prolific in recruiting than other locations, current sites on might/could contribute (i.e., treat) between 5 and 20 patients per month. Several to 12 weeks, or more, would be required for an event to be generated from the use of chemotherapy or T-Vec. Takeaway: Such general math could support an interim readout as early as late-1Q17 or as late as early-3Q17.

    Third quarter. Provectus will hold its 3Q16 business update conference call on November 14th (press release here, associated 8-K filing here). The 10-Q report could be filed on November 9th.

    Updated (10/25/16).3: H/t a regular hatter for the following that mention PV-10:
    Visitors (October 23, 2016)

    I last updated visits by [U.S. and international] pharmaceutical and biotechnology companies (that I could identify) to the blog in April. The measurement period was from about December 2015 to about April 2016 (i.e., four months). See Visitors (April 6, 2016) on the Archived News V blog page.
    Click to enlarge. Timeframe: ~December 2015 to ~April 2016
    Visits comprised multiple visits on multiple days by multiple IP addresses (category A), multiple visits on multiple days by a single IP address, a single visit on multiple days by multiple IP addresses, and a single visit on a single day by a single IP address. These data (not comprehensive), now from about June to about October 2016, are summarized in the table below.
    Click to enlarge. Timeframe: ~June to ~October 2016
    Comparing category A between the two time periods are below, based on rankings of both total revenues and oncology revenues.
    Click to enlarge
    Click to enlarge
    Non-inflamed (excluded) (October 21, 2016)

    Consider "Immune Escape to PD-L1/PD-1 Blockade, Seven Steps to Success (or Failure)," Kim et al., Ann Oncol. 2016;27(8):1492-1504. One of the co-authors is Dr. Daniel Chen, PhD, who co-conceived The Cancer Immunity Cycle. A modified image of the cycle is below.
    Click to enlarge. Image source
    The authors write:
    "For any tumor type, individuals may present with cancer that is inflamed or noninflamed (excluded or immune deserts). However, certain tumor types appear to present more commonly with specific immune findings. Tumors such as melanoma, lung, kidney, and urothelial cancer often present as inflamed, whereas colorectal and pancreatic cancers often present as excluded and prostate cancer often presents as noninflamed immune deserts. Common characteristics of responding inflamed tumors include dense CD8+ T-cell infiltrates, a broad chemokine profile, PD-L1 expression on immune cells, a type 1 interferon (IFN) signature, and elevated expression of IFN-γ–induced genes." {my underlined emphasis}
    Moffitt Cancer Center will present preclinical data at SITC 2016; see September 26th blog post
    SITC 2016: Intralesional injection with Rose Bengal and systemic chemotherapy induces anti-tumor immunity in a murine model of pancreatic cancer. All we have is an abstract title...for now (where I believe the chemotherapy is gemcitabine). The lead Moffitt author is Moffitt PV-10 team member Dr. Shari Pilon-Thomas, PhD.

    Dr. Pilon-Thomas' past work on pancreatic cancer has included {my bolded emphasis}:
    • 2015: "Murine Pancreatic Adenocarcinoma Reduces Ikaros Expression and Disrupts T Cell Homeostasis," Nelson et al., PLoS One. 2015; 10(1): e0115546: "Maintenance of T cell immune homeostasis is critical for adequate anti-tumor immunity. The transcription factor Ikaros is essential for lymphocyte development including T cells. Alterations in Ikaros expression occur in blood malignancies in humans and mice. In this study, we investigated the role of Ikaros in regulating T cell immune balance in pancreatic cancer mouse models."
    • 2016: "Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors," Hall et al., Journal for ImmunoTherapy of Cancer 2016 4:61: "TIL expanded from pancreatic tumors are functional and able to respond to pancreatic tumor associated antigens. PD-1 blockade, 41BB stimulation, and CD8+ T cell enrichment are effective strategies to improve TIL yield and tumor reactivity. These results support the development of adoptive cell therapy strategies using TIL for the treatment of pancreatic cancer."
    Revised preliminary. Provectus filed a revised preliminary proxy statement (Schedule 14A) today. The prior, initial preliminary statement (Schedule 14A) was filed on October 5th. The date of the shareholder meeting was moved to November 21st from November 14th. I understand the meeting date had to be later because it would appear more time is required for the preliminary proxy (now revised) to become definitive (final). The October 17th date for stockholders of record remained the same. There were a few other changes highlighted by comparing the documents using Text Compare!

    Special proxy vote. We plan to vote for proposal #1, which seeks to increase the authorized number of shares of 400 million to 1 billion, and against proposal #2, which seeks to effect a reverse stock split at a ratio to be determined by Provectus' board in its discretion. I will post our vote on the blog, together with associated rationale, closer to the meeting date.

    Board of directors. While there would seem to be very serious and pragmatic reasons to support the first proposal (e.g., to meet the obligation of the price protection provisions of the August preferred stock and warrant offering) (it's a calculation at this point, and thus should [hopefully] be idiot-proof), I am hard pressed to further entrust other as or more serious decisions — like the second proposal — to inexperienced independent members (e.g., a party planner/emerging comedian, a real estate agent, and a physician) with no capital markets experience who already have proven themselves to be extremely unserious.

    Time flies. InvestorVillage poster ReturnOfJuggernaut reminds of PH-10-related comments by Provectus management more than a year ago in a BioPharm Insight article entitled "Provectus Biopharmaceuticals to start two Phase III dermatology trials mid­ 2016, will entertain CRO pitches – exec:"
    "Provectus Biopharmaceuticals (NYSEMKT:PVCT) is planning to start two Phase III trials for its psoriasis and atopic dermatitis treatment PH­10 by mid­ 2016, with CROs to be named in 1Q16, Chief Technology Officer Eric Wachter said... 
    The psoriasis trial will likely start sometime before the atopic dermatitis trial, Wachter said. While both studies are intended to be in adults, since atopic dermatitis is principally a paediatric disease, it could be harder to find adult patients to enroll, he said. 
    Both Phase III studies will likely have around 200 patients and be randomised but the psoriasis study could expand because visible results don't seem to appear until the fourth week of use, he added. In the psoriasis program, PH­10 efficacy will be compared with either a placebo or an active comparator.  The comparator would be decided in 1Q16, Wachter said. The primary endpoint is expected to be based on the Psoriasis Area and Severity Index at week 12, he noted... 
    Provectus is open for global licencing deals with big pharma for PH­10 for future development and commercialisation, Chief Financial Officer Peter Culpepper said. A deal will likely be finalised after the data is available from the company's PH­10 mechanism ­of ­action (MOA) Phase II trial (NCT02322086) or potentially after its meeting with FDA in 1H16, he said. 
    The MOA trial's estimated primary completion date is in December, states. Asked if they are in active licensing talks, Culpepper said details are confidential but added the company's ideal licensee would be global players like Novartis (VTX:NOVN), Lausanne, Switzerland­based Galderma, Parsippany, New Jersey­ based Leo Pharma or Pfizer (NYSE:PFE) that have a focus on dermatological therapeutics. {my underlined emphasis}

    (now titled "Archived News VI")

    No comments:

    Post a Comment